Novel approaches to identify small molecules
modulating E.coli TolC protein function
by
Alessia Gilardi
A thesis submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
in Biochemistry
Approved Dissertation Committee
Prof. Dr. Mathias Winterhalter (Jacobs University Bremen)
Prof. Dr. Richard Wagner (Jacobs University Bremen)
Dr. Philip Gribbon (Fraunhofer IME – SP)
Dr. Björn Windshügel (Fraunhofer IME – SP)
Date of Defense: 14.07.2017
Life Sciences and Chemistry Department
II
III
Statutory Declaration
Family Name, Given/First Name Gilardi, Alessia
Matriculationnumber 20331309
What kind of thesis are you submitting: Bachelor‐, Master‐ or PhD‐Thesis PhD Thesis
English: Declaration of Authorship
I hereby declare that the thesis submitted was created and written solely by myself without any external support. Any sources, direct or indirect, are marked as such. I am aware of the fact that the contents of the thesis in digital form may be revised with regard to usage of unauthorized aid as well as whether the whole or parts of it may be identified as plagiarism. I do agree my work to be entered into a database for it to be compared with existing sources, where it will remain in order to enable further comparisons with future theses. This does not grant any rights of reproduction and usage, however.
The Thesis has been written independently and has not been submitted at any other university for the conferral of a PhD degree; neither has the thesis been previously published in full.
German: Erklärung der Autorenschaft (Urheberschaft)
Ich erkläre hiermit, dass die vorliegende Arbeit ohne fremde Hilfe ausschließlich von mir erstellt und geschrieben worden ist. Jedwede verwendeten Quellen, direkter oder indirekter Art, sind als solche kenntlich gemacht worden. Mir ist die Tatsache bewusst, dass der Inhalt der Thesis in digitaler Form geprüft werden kann im Hinblick darauf, ob es sich ganz oder in Teilen um ein Plagiat handelt. Ich bin damit einverstanden, dass meine Arbeit in einer Datenbank eingegeben werden kann, um mit bereits bestehenden Quellen verglichen zu werden und dort auch verbleibt, um mit zukünftigen Arbeiten verglichen werden zu können. Dies berechtigt jedoch nicht zur Verwendung oder Vervielfältigung.
Diese Arbeit wurde in der vorliegenden Form weder einer anderen Prüfungsbehörde vorgelegtnoch wurde das Gesamtdokument bisher veröffentlicht.
…………………………………………………………………………………………………...
Date, Signature
IV
V
To my lovely family, always on my side.
VI
VII
“Considerate la vostra semenza:
Fatti non foste a viver come bruti,
ma per seguir virtute e canoscenza”
Divina Commedia, Canto XVI (vv. 118-120)
Dante Alighieri
VIII
IX
Table of Contents
Abstract ................................................................................................................................... XI
Acknowledgements .............................................................................................................. XIII
Funding .......................................................................................................................... …..XIV
Aim of the work ..................................................................................................................... XV
Chapter 1. Introduction ........................................................................................................... 1
1.1 Antibiotic resistance ......................................................................................................... 1
1.2 Gram-negative bacteria pathogenicity and treatments .................................................... 3
1.3 Gram-negative bacteria and their membrane structure .................................................... 4
1.4 Efflux pumps ................................................................................................................... 7
1.5 Structure of AcrAB-TolC ................................................................................................. 9
1.6 TolC ................................................................................................................................ 11
1.7 Role of efflux pump inhibitors as adjuvants ................................................................... 12
References ............................................................................................................................. 15
Chapter 2. Biophysical characterization of the interaction between E. coli TolC
interaction and hexaamminecobalt ....................................................................................... 19
2.1 Introduction ..................................................................................................................... 21
2.2 Material and methods .................................................................................................... 24
2.3 Results and discussion ................................................................................................... 27
2.3.1 Voltage-dependent TolC opening and asymmetric behavior .................................. 27
2.3.2 Hexaamminecobalt blocks TolC opening ............................................................... 29
2.3.3 Binding affinity of hexaamminecobalt .................................................................... 31
2.3.4 Hexaamminecobalt does not possess antimicrobial activity in E. coli strains ......... 35
2.4 Conclusions.................................................................................................................... 37
References ............................................................................................................................. 39
Annex Chapter 2 (A2) .......................................................................................................... 41
Chapter 3. Identification of small molecules binding TolC through in silico studies and
their biophysical validation ................................................................................................... 45
3.1 Introduction ..................................................................................................................... 47
3.2 Material and methods .................................................................................................... 49
X
3.3 Results............................................................................................................................ 53
3.3.1 Hit identification and validation ............................................................................. 53
3.3.2 Biophysical hit characterization .............................................................................. 56
3.3.3 Antimicrobial activity assays ................................................................................... 59
4.4 Discussion ...................................................................................................................... 63
References ............................................................................................................................. 65
Annex Chapter 3 (A3) .......................................................................................................... 69
Chapter 4. Conclusion and outlook ..................................................................................... 77
List of figures and tables ....................................................................................................... 81
List of Publications ................................................................................................................ 83
XI
Abstract
The urge of new strategies to overcome the world wide health problem of antibiotic resistance
induced researchers as well governmental and private institution to come together to increase
the medical and scientific knowledge on this topic.
This PhD project is part of the ITN Translocation, whose aim was to investigate the molecular
and cellular mechanism at the basis of influx and efflux processes in gram-negative bacteria.
The work behind the scientific advances reached during my 3-year-journey has been
accomplished mainly between the Fraunhofer IME ScreeningPort in Hamburg and the Jacobs
University Bremen, enriched by external collaborations with the University of Frankfurt and
the Helmholtz Center for Infection Research.
Through an interdisciplinary approach, from in silico studies to biophysical characterization in
vitro, small molecules hits to be developed as efflux pump inhibitors (EPIs) were identified. In
particular, these compounds were shown to bind TolC, part of the major efflux systems in
E.coli, in docking studies targeting an acidic pocket present in the periplasmic tip of the
channel; to selectively bind TolCWT against a recombinant version, where key residues in the
target site are mutated, in a biophysical setup allowing the determination of binding constant;
to modulate ion current in reconstituted TolCWT in single-channel electrophysiology
measurements.
Overall, the findings reported in this PhD thesis increase the knowledge of the biophysical
characteristics of TolC through the use of cutting-edge methods and technologies, in particular
in the field of membrane channels, and allowed the identification of promising compounds hits
to support the development of EPIs to be employed as adjuvants in antimicrobial therapies.
XII
XIII
Acknowledgements
This PhD has been for me a wonderful journey, not only from a scientific point of view but also
from a personal perspective. A MSCA fellowship does not only give the possibility to do
science, but gives also the opportunity to create a unique network without boundaries of any
kind and to meet amazing people around the World.
First, I would like to thank my mentor, Dr. Philip Gribbon, for giving me the great chance of
getting this fellowship and for constantly encouraging my work throughout these years. Thanks
to Dr. Björn Windshügel for introducing me to the dark and fascinating world of computational
biochemistry and being a great supervisor. A special mention goes to Prof. Mathias
Winterhalter for welcoming me in his group and being my PhD advisor.
A special acknowledgement goes to the Fraunhofer IME ScreeningPort group: Carsten, Mira,
Markus, Gesa, Lea, Manfred, Jeanette, Jennifer, Oliver, Bernhard, Sheraz, Ole, Rashmi, Maria,
Nina and last, but not least, my personal supporters, Elisa, Adelia, Thales and Laura. Thanks
for making the time in the lab and in the office less stressful and sharing with me daily pain and
achievements.
Thanks to my ITN Translocation colleagues, whom I had the pleasure to share few of the most
demanding and still inspiring meetings with: Silvia, Venkat, Satya, Jenifer, JJ, Luana,
Sushovan, Fabio, Pauline, Monisha and Vincent.
To conclude, I would like to thank my German acquired family, my friends and in particular
Chris for being always present with unconditional love and for making me feel home.
I want to dedicate this achievement especially to my parents, which with no hesitation and
unlimited support helped me to follow my dreams and arrive till here, step by step, always on
my side.
XIV
Funding
This work was financially supported by the Initial Training Network Translocation (ITN-2014-
607694-Translocation) as part of the Marie Skłodowska-Curie fellowships and by the
Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), department
ScreeningPort.
XV
Aim of the work
This project started with the aim of identify new approaches to fight antibiotic resistance not
by the direct discovery of novel antimicrobial molecules, but seeking to improve the efficacy
and extend the usage of the already available drugs.
Because of the time intensive processes necessary for the development of new antibiotic drugs
and the well described low success rate in taking a project from a target to the clinic, it has
become of crucial importance to find different strategies to fight the health crisis of antibiotic
resistance.
One of the main mechanism used by gram-negative bacteria to eliminate of toxic compounds
such as antibiotics, is to relocate them from the cytoplasmic or periplasmic environment to the
extracellular space through the so called efflux systems. Efflux systems can be categorized in
different families, with different structural organizations and phylogenetical classifications.
In E. coli, the most studied and better characterized efflux system is the AcrAB-TolC efflux
pump and in the last years a lot of effort has been addressed in the identification of efflux pump
inhibitors (EPIs), blocking the extrusion of antibiotics, thereby increasing their time of exposure
to intracellular targets and the opportunity to kill bacterial cells.
Most of the EPIs discovered so far targeted the inner membrane protein AcrB or the membrane
fusion protein or adaptor protein AcrA, but not the outer membrane protein TolC.
With this study we want to re-establish the importance of blocking TolC, which represents the
last step of the translocation of antibiotics in efflux complexes as AcrAB-TolC, but also
AcrAD-TolC or MecAB-TolC. Blocking this channel might lead to the positive consequence
of increasing the efficacy of known antibiotics and therefore improve antimicrobial therapies
employing these compounds as adjuvants.
XVI
1
Chapter 1
Introduction
1.1 Antibiotic resistance
The term antibiotic refers to substances used to treat bacterial infections and which are capable
of killing, reducing the growth or limiting the fitness of bacterial microorganisms. Initially this
term applied mainly to “natural” antimicrobial substances (produced by other microorganisms)
and is now extended also to synthetic compounds, which in many cases are structurally related
to their natural counterparts. While the existence of antibiotics has been known since the ancient
times and treatments of microbial infections are well-documented in Egyptian, Greek and
Chinese cultures1, the modern (so called golden) era of antibiotics started with the discovery
and clinical application of penicillin followed by a whole series of other antibiotic compound
classes2. Unfortunately, along with the discovery of antibiotic compounds, there was an almost
contemporaneous observation of the emergence of antibiotic resistant strains, which via a
cumulative process over the course of time has led to the onset of the so called “resistance era”
(Fig.1.1).1,3
The antimicrobial substances produced at sub-lethal concentrations by microorganisms are
involved in several physiological mechanisms, such as signaling, virulence, host-parasite
interactions, quorum sensing and other effects4. The use of higher concentrations of antibiotics
for treatments of human and animal infections has led to an upsurge of antibiotic-resistant
pathogens within a short amount of time. The associated antibiotic resistance related genes,
which were once involved in other cellular functions, have been subsequently selected for
resistance phenotypes as a consequence1,4.
Chapter 1
2
Figure 1.1 Model of antibiotics discovery and development (Antibacterial drug discovery in the resistance era
Brown, E. D. & Wright, G. D., Nature, 2016 (doi:10.1038/nature17042)5
Chapter 1
3
1.2 Gram-negative bacteria pathogenicity and treatments
Bacterial species can be classified mainly according to their morphological and biochemical
characteristics. In the case of pathogenicity and medical interest, species classification also
utilizes serology, toxin identification and/or gene sequencing information6.
With regard to the classification of species involved in severe infections for human beings and
animals, a key group of bacterial culprits has been identified. ESKAPE is the acronym given to
this group of bacteria, which includes both Gram-positive and Gram-negative species, made up
of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species. These bacteria species are
common causes of life-threatening nosocomial infections amongst critically ill and
immunocompromised individuals and are characterized by multiple potential drug resistance
mechanisms7.
Recently, the WHO (World Health Organization) have published a list of bacteria for which
new antibiotics or strategies to overcome their developed resistance to known antimicrobials is
urgent8. In the three categories, according to the priority need for new therapeutic agents, we
can find at the highest level carbapenem-resistant strains of A. baumannii, P. aeruginosa and
Enterobacteriaceae. In the next risk categories are methicillin-resistance strains of S. aureus
(MRSA), vancomycin-resistance in E. faecium and S. aureus, and fluoroquinolone-resistance
found in Campylobacter spp., Salmonellae, N. gonorrhoeae strains. E. coli is not listed in this
group, because only a restricted number of strains part of this gram-negative species are
pathogenic. Although, they can lead to deadly infections in particular when strains exhibit
MDR9.
In developing antibiotic resistance, evolutionary forces have led bacteria to evolve a series of
mechanisms of protection, spanning from mechanical barriers, e. g. membrane envelope, to
expression regulation of proteins and enzymes, e.g. porins and efflux systems, which allow
them to overcome the antibacterial action of the toxic molecules10,11.
Chapter 1
4
1.3 Gram-negative bacteria and their membrane structure
All cells, being part either of the Eucarya, Eubacteria or Archea domain, possess an external
protection provided by the cell membrane. The cell membrane or envelope is a complex
multilayered system which confers protection and support to the cell structure as well as
modulating the interactions and exchanges between external environment and internal cell
compartments.
In bacteria, cell envelope properties contribute to the phenotypic classification of different
organisms. Indeed, based on the Gram staining developed in 1884, it is possible to discriminate
between Gram-positive and Gram-negative bacteria on the basis of differential staining using a
crystal violet-iodine complex and a safranin counterstain, which interacts with the
peptidoglycan in the cell wall13,14.
The cell envelope of most bacteria can be divided in two major groups, based on their structural
features. Gram-positive bacteria present a thick multi-layer of peptidoglycan through which are
inserted long anionic polymers. Gram-negative bacteria, on the other side, present a more
compact peptidoglycan layer, which is surrounded by a cell wall of lipopolysaccharide (LPS)14.
The complex structure of the Gram-negative bacteria outer membrane, compared to that of
gram-positive bacteria, confers an extra layer of protection to the microorganisms whilst still
maintaining an effective physiological exchange of materials with the external environment15.
The permeability properties of this barrier have a major impact on the susceptibility of the
microorganism to antibiotics, which target essential intracellular processes. Small hydrophilic
drugs, such as β-lactams, use the pore-forming porins to gain access to the cell interior, while
macrolides and other hydrophobic drugs diffuse across the lipid bilayer15,16.
The so-called intrinsic resistance of gram-negative bacteria is commonly attributed, together
with other factors, to the presence and function of the outer membrane barrier. The barrier
contributes to the resistance through different ways, e.g. slowing down the penetration of small
hydrophilic solutes by means of the action of porin channels, and by decreasing the
transmembrane diffusion of lipophilic molecules thanks to the relatively low fluidity of the
lipopolysaccharide leaflet17. The acquisition of resistance pathways, mechanism of action and
antibiotic targets are described in Fig. 1.2.
Since the membrane envelope represents a selective permeability envelope for bacterial cells,
they evolved different mechanisms to allow the uptake of nutrients through the outer membrane
and porins are one of these mechanisms. Porins are water-filled pores that extend across the
outer membrane and promote the access of hydrophilic compounds up to a certain size
Chapter 1
5
exclusion limit11. Different porins have been characterized from gram-negative bacteria and
from mycobacteria, since the first one has been identified from E. coli in 197618.
These proteins are present in the outer membrane of gram-negative bacteria and they act to
select the hydrophilic compounds determined by the diameter of the channels. The structure of
porins is different compared to other membrane proteins; in that they lack the classic
hydrophobic region and consist of transmembrane antiparallel β-strands with alternating
hydrophobic (facing outwards) and hydrophilic (facing inwards) aminoacids assembled into
distinctive β-barrels rather than hydrophobic α-helices, which are more often found in proteins
located in the cytoplasmic membrane19.
The predominant function of the general porins, e.g. OmpF and PhoE of E. coli, is to create a
size-selective defined channel for the diffusion of hydrophilic molecules with some preference
for molecules with charges opposite those of the amino acids lining the channels11,20. Although,
not only essential nutrients for bacterial survival, but also specific antibiotics are able to
penetrate the membrane envelope taking advantage of porins presence. Β-lactams and
fluoroquinolones are the two main classes of active antibiotics against Gram-negative bacteria.
In particular β-lactams are small and hydrophilic drugs that enter the cells via the general porins.
Nevertheless, many bacteria have developed strategies based on porin modifications to limit β-
lactam influx, e.g. exchange in the type of porin expressed, change in the level of porin
expression, mutations or modifications that impair the functional properties of the channel20,21.
However, a second major contribution to the aforementioned intrinsic resistance is endowed by
the presence of multiple efflux pumps capable of selecting and then removing agents deleterious
to cell health, such as antibiotics, from the cell22.
Chapter 1
6
Figure 1.2 Antibiotic resistance: acquisition pathways, main mechanisms and antibiotic targets (targeting
Antibiotic Resistance, M. F. Chellat, L. Raguž, R. Riedl, Angew. Chem. Int. Ed. 2016, 55, 6600.
(doi:10.1002/anie.201506818)12
Chapter 1
7
1.4 Efflux pumps
Efflux pumps are involved not only in bacterial intrinsic resistance, but also in acquired
resistance, developed through genetic mutations or horizontal gene transfer, and phenotypic
resistance, arising from induction of increased efflux pump expression23.
The classification of the various efflux transporters is based on their functional and
phylogenetic properties, which has led to 6 distinct efflux pump families being described24–26:
the RND (resistance nodulation division), MFS (major facilitator superfamily), MATE
(multidrug and toxic compound extrusion), SMR (small multidrug resistance), and ABC (ATP-
binding cassette) and PACE (proteobacterial antimicrobial compound efflux) families. All but
one family of transporters are dependent on proton motive force, for this reason they are also
considered secondary transporters or proton/drug antiporters. ABC transporters, in contrast,
utilize ATP hydrolysis as their energy source (schematic representation in Fig. 1.3).
The RND transporters play a prominent role in the antimicrobial resistance of gram-negative
bacteria. These tripartite complexes, which are all exporters of drugs and toxic cations, span
from the inner membrane (IM) to the outer membrane (OM). The proton motive force
components are located in the IM (cytoplasmic membrane), but must interact with the
periplasmic adaptor protein (also called the membrane fusion protein, MFP) and the OM
channel, thus producing a tripartite complex. Well studied examples of these complexes are
represented by E. coli AcrAB-TolC and P. aeruginosa MexAB-OprM. Furthermore, some
members of the ABC superfamily (e.g., MacB), the MATE family (e.g., MdtK), and the MFS
(e.g., EmrB) are also organized in this manner. The key functional role of the tripartite
transporters lays in their ability in excrete drugs directly into the external medium so that the
reentry of the same drugs would require the slow traversal of the OM27.
Chapter 1
8
Figure 1.3 Diagrammatic comparison of the five families of efflux pumps (Clinically Relevant Chromosomally
Encoded Multidrug Resistance Efflux Pumps in Bacteria, L.J.V. Piddock, Clin. Microbiol. Rev. April 2006 vol.
19 no. 2 382-402, doi: 10.1128/CMR.19.2.382-402.2006)22
Chapter 1
9
1.5 Structure of AcrAB-TolC
As described above, E. coli AcrAB-TolC is a well-studied example of an RND transporter
protein complex. The three components that form the complex are the IM transporter AcrB, the
OM channel TolC, and the MFP (or periplasmic adaptor) AcrA, which plays a main role in
stabilizing the interaction between AcrB and TolC28,29.
AcrB functions as the transporter and is organized in the form of an asymmetrical homotrimer30
in which each protomer assumes a different conformation, reflecting a distinct step in the
translocation process. These conformations have been described as loose (L), tight (T) and open
(O), which represent respectively the initial interaction (L), poly-specific binding (T) and
extrusion of substrate(s) to the TolC channel(O)31,32. To induce a conformational change
through the different states, proton motive force is required, which is transduced by means of
the transmembrane domain of AcrB31,33. The antiporter AcrB captures its substrates and
transports them into the external medium via the OM channel TolC and the cooperation between
AcrB and TolC is thought to be mediated by the periplasmic protein AcrA34,35.
Several models have been proposed to explain the interaction between AcrA, AcrB and
TolC28,35–37, with the aim to elucidate which are the steps that induce TolC to change its
conformation from closed to open, in order to allow the passage of substrates translocated by
AcrB. The “adaptor wrapping model” describes how AcrB and TolC might directly interact to
induce the opening of TolC, supported by AcrA. TolC switching conformation from closed to
open would then induce the disassembly of the complex35,38. Currently, this model has yet to
be confirmed by structural studies. A second proposed model to describe the interaction
between AcrAB-TolC components is the “adaptor bridging model”. Here, the channel opening
of TolC is thought to be induced by the binding of AcrA28,39,40. More precisely, the residues
responsible for the closing of TolC (Thr152, Asp153, Tyr362, and Arg367)38 are moved to the
binding interface with AcrA. This suggests that the TolC residues involved in the complex
formation with AcrA are the same as those involved in the closing of the TolC channel.
In partial agreement with the “adaptor bridging model”, more insights on the AcrA-TolC
interaction are given by Wang and collaborators29. In this description, structures of the full
pump assembly with a closed OM channel (TolC) in the apo-state represent the resting state,
whereas an open channel in the presence of inhibitor or antibiotic represents the transport state
(Fig. 1.4). Through this analysis, these authors suggest that the binding of a ligand in the apo-
state induces changes in the quaternary structure of AcrB, that are transferred to AcrA, which
Chapter 1
10
repacks and in turn affects the tertiary structure of TolC, causing a switch from resting to
transport state, i.e. from a closed to an open conformation29.
Figure 1.4 Schematic cartoon of the transport mechanism: (A) the resting state of the apo pump with TolC in
closed-state and the AcrB trimer in LLL conformation. (B) The apo pump switches to a transport-state in the
presence of transport substrate (s), opening the TolC channel (right arrow). In the transport-state, AcrB cycles
through three, structurally distinct states (L, T and O), two of which are shown in the left panel (T and O). Cycling
is obligatory for unidirectional transport, driven by coupling with transmembrane proton conduction through the
TM domain (red arrow). In the absence of substrate, the pump reverts to the resting state and closes the TolC
channel (left arrow). The views are cross-sections through the cell envelope, with only two monomers shown for
each of the pump components. The inset cartoons on the left in (A) and the right in (B) show views down the
molecular axis of the AcrB trimer, indicating the states with the configuration inferred from the cryoEM
reconstructions. The model predicts a contraction along the long axis of the pump with the switch from apo- to
transport-states. (An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump, Wang, Z. et
al.Elife 6, 759–796, 2017 (doi:10.7554/eLife.24905)29
Chapter 1
11
1.6 TolC
Synthesis of TolC takes place in the cytoplasm of E. coli and the channel is then transported
across the inner membrane and into the periplasm. In the cytoplasm, chaperones of the Sec
(secretion) machinery target the cleavable N-terminal signal peptide, generating a mature 471-
aminoacid TolC, which folds and assembles in the periplasm41. Unlike other OMPs, the
assembly of TolC trimers is independent from known periplasmic chaperones and a signal
sequence-less mature TolC has been shown to fold and form trimers, even in the cytoplasm.
This suggests that external factors for TolC assembly are not required42.
The TolC structure was solved by Koronakis and collaborators43 using X-ray crystallography
and further analyzed in its different putative opened conformations44,45. TolC appears as a
cannon-shaped channel, with a long axing of 140 Å, of which ~ 100 Å form a uniform cylinder.
The distal (upper) end of the structure is formed by a β-barrel which is open and provides
solvent access. This relatively rigid structure is located in the OM and is assembled from three
monomers, each contributing four β-strands. In contrast, the proximal (lower) end of the
structure substantially narrows, leading to a constriction region. The constricted region is
formed by an α-helical barrel, contiguous with the β-barrel, and extends into the periplasm43.
The internal diameter of TolC is ~ 35Å for most of the periplasmic tunnel length, with the
channel exit to the outside constitutively open. In contrast, towards the bottom of the
periplasmic end, three of the six pairs of α-helices fold inwards and serve to constrict the
periplasmic entrance down to a diameter of ~ 4 Å. This structure organization reflects and
explains the previous observation that although TolC forms an ion-permeable channel, when
the channel is reconstituted into lipid bilayers, its conductance is relatively low (about 80
pS)46,47 compared to classical membrane channels such as E. coli OmpF, which has a
conductance of ~ 4 nS48,49.
Chapter 1
12
At the periplasmic entrance, where the constriction region is situated, a ring of six aspartates,
Asp371 and Asp374, (provided by the 3 monomers) are located at consecutive helical turns43,50.
Structural and biophysical analyses have shown that these aspartates play an important role in
defining channel properties including pH dependence and cation selectivity44,47. The transport
properties of several cationic species through TolC have been analyzed in electrophysiology
experiments50. In particular the interaction of TolC with the small charged molecule
hexaamminecobalt has been successfully validated through the elucidation of a TolC-
hexaamminecobalt co-crystal structure51. Hexaamminecobalt is able to block ion currents
through reconstituted TolC in an artificial bilayer configuration47,52. Nevertheless,
hexaamminecobalt has not been reported to show any direct antimicrobial activity or synergistic
effects with known antibiotics which are substrates of efflux pumps. These findings emphasize
that, in order to reach the full potential of TolC as transport related target, the identification of
a new class of EPIs (Efflux Pump Inhibitors) compounds addressing TolC is a critical first step.
1.7 Role of efflux pump inhibitors as adjuvants
As described in the previous paragraph, EPIs could be useful as adjuvants in association with
antimicrobial therapies to improve antibacterial potency, by increasing the intracellular
concentration and the effective period of time that antibiotics are able to interact with their
primary target. This would also have potential positive effects in mitigating the emergence of
phenotypic resistance, e.g. inhibiting biofilm formation, and decreasing virulence of enteric
pathogens53.
A family of peptidomimetics, including PAβN (MC-207110), that exhibited potent inhibition
of efflux pumps in P. aeruginosa has been developed for use as an adjunctive therapy54 .
Although some of these inhibitors were validated using in vivo infection models, they were
abandoned because the positive charged moieties that were required for activity in P.
aeruginosa caused nephrotoxicity55. In addition, a series of pyridopyrimidine EPIs that are
specific for the MexAB efflux pump of P. aeruginosa progressed from early discovery to the
preclinical stage56,57.
Chapter 1
13
For E. coli, a class of EPIs targeting AcrB have been described. These compounds, which
include MBX2319 and its derivatives, were shown to increase the potency of a broad range of
antibiotics against E. coli and other Enterobacteriaceae, whilst not exhibiting membrane-
disrupting or other antibacterial type activity53,58.
Recently, new approaches targeting the MFP AcrA in order to disrupt the efflux complex or
disturb its formation were reported59, but further steps towards the development of clinical
candidates are still necessary.
The presented examples of identification of EPIs are all the result of cell-based screenings of
large compound libraries followed by secondary assays for validation of potency and target
specificity54,60. The exception is the methodology used to identify the AcrA inhibitors which
were developed as part of a parallel experimental and structure-based computational screens
which included merging the results of the two parallel approaches for the hit validation.
Based on the outcome of the studies presented in this overview is clear that there has been a
lack of structurally informed and target-focused approaches used to discover novel EPIs. We
therefore decided to develop a structure-based approach followed by experimental validation
of the promising adjuvants targeting TolC for the identification of blockers which could serve
as a new class of EPIs. Furthermore, targeting TolC gives the possibility to identify blockers
which could modulate the efflux not only of the major E. coli efflux pump AcrAB-TolC, but
also secondary systems involved in the efflux, such as AcrAD-TolC or MecAB-TolC, which
TolC forms complexes with. A secondary benefit, due to the high structural similarity
throughout TolC homologues across different gram-negative species, is the potential to have a
broad spectrum adjuvant properties across multiple pathogenic bacteria.
Chapter 1
14
Chapter 1
15
References:
1. Sengupta, S., Chattopadhyay, M. K. & Grossart, H. P. The multifaceted roles of antibiotics and antibiotic resistance in nature. Front. Microbiol. 4, 1–13 (2013).
2. Brown, D. Antibiotic Resistance Breakers: Can repurposed drugs fill the antibiotic discovery void? Nat.
Rev. Drug Discov. In Press, 821–832 (2015).
3. Lobanovska, M. & Pilla, G. Penicillin’s Discovery and Antibiotic Resistance: Lessons for the Future? Yale J. Biol. Med. 90, 135–145 (2017).
4. Holmes, A. H. et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387, 176–187 (2016).
5. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. Nature (2016). doi:10.1038/nature17042
6. Baron, E. J. Classification. Medical Microbiology (University of Texas Medical Branch at Galveston, 1996).
7. Santajit, S. & Indrawattana, N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed
Res. Int. 2016, 2475067 (2016).
8. WHO | WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO (2017).
9. Johnson, J. R. et al. Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli. J. Infect. Dis. 207, 919–928 (2013).
10. Escherichia coli - Infectious Disease and Antimicrobial Agents. Available at: http://www.antimicrobe.org/b104.asp. (Accessed: 13th June 2017)
11. Fernández, L. & Hancock, R. E. W. Adaptive and mutational resistance: Role of porins and efflux pumps in drug resistance. Clin. Microbiol. Rev. 25, 661–681 (2012).
12. Chellat, M. F., Raguz, L. & Riedl, R. Targeting Antibiotic Resistance. Angew. Chemie - Int. Ed. 55, 6600–6626 (2016).
13. Moyes, R. B. et al. in Current Protocols in Microbiology A.3C.1-A.3C.8 (John Wiley & Sons, Inc., 2009). doi:10.1002/9780471729259.mca03cs15
14. Silhavy, T. J., Kahne, D. & Walker, S. The bacterial cell envelope. Cold Spring Harb. Perspect. Biol. 2, a000414 (2010).
15. Delcour, A. H. Outer Membrane Permeability and Antibiotic Resistance. Biochim Biophys Acta. 1794, 808–816 (2009).
16. Galdiero, S. et al. Microbe-host interactions: structure and role of Gram-negative bacterial porins. Curr.
Protein Pept. Sci. 13, 843–54 (2012).
17. Nikaido, H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178, 5853–5859 (1996).
18. Nakae, T. Identification of the outer membrane protein of E. coli that produces transmembrane channels in reconstituted vesicle membranes. Biochem. Biophys. Res. Commun. 71, 877–884 (1976).
19. Cowan, S. W. et al. Crystal structures explain functional properties of two E. coli porins. Nature 358, 727–733 (1992).
20. Masi, M. & Pagès, J.-M. Structure, Function and Regulation of Outer Membrane Proteins Involved in Drug Transport in Enterobactericeae: the OmpF/C - TolC Case. Open Microbiol. J. 7, 22–33 (2013).
21. Kumar, A., Hajjar, E., Ruggerone, P. & Ceccarelli, M. Translocation through OmpF. 9608–9616 (2010).
22. Piddock, L. J. V. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19, 382–402 (2006).
Chapter 1
16
23. Blanco, P. et al. Bacterial Multidrug Efflux Pumps: Much More Than Antibiotic Resistance Determinants. Microorganisms 4, 14 (2016).
24. Li, X. Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
25. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453, 254–267 (2014).
26. Hassan, K. A., Liu, Q., Henderson, P. J. F. & Paulsen, I. T. Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems. MBio 6, e01982-14 (2015).
27. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol.
Rev. 67, 593–656 (2003).
28. Jeong, H. et al. Pseudoatomic Structure of the Tripartite Multidrug Efflux Pump AcrAB-TolC Reveals the Intermeshing Cogwheel-like Interaction between AcrA and TolC. Structure 24, 272–276 (2016).
29. Wang, Z. et al. An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump. Elife 6, 759–796 (2017).
30. Seeger, M. a et al. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313, 1295–1298 (2006).
31. Eicher, T. et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB. Elife 3, (2014).
32. Pos, K. M. Drug transport mechanism of the AcrB efflux pump. Biochim. Biophys. Acta 1794, 782–93 (2009).
33. Su, C.-C. et al. Conformation of the AcrB multidrug efflux pump in mutants of the putative proton relay pathway. J. Bacteriol. 188, 7290–6 (2006).
34. Tikhonova, E. B. & Zgurskaya, H. I. AcrA, AcrB, and TolC of Escherichia coli form a stable intermembrane multidrug efflux complex. J. Biol. Chem. 279, 32116–32124 (2004).
35. Tikhonova, E. B., Yamada, Y. & Zgurskaya, H. I. Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC. Chem. Biol. 18, 454–463 (2011).
36. Du, D. et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature 509, 512–5 (2014).
37. Kim, J.-S. et al. Structure of the Tripartite Multidrug Efflux Pump AcrAB-TolC Suggests an Alternative Assembly Mode. Mol. Cells 38, 180–186 (2015).
38. Bavro, V. N. et al. Assembly and Channel Opening in a Bacterial Drug Efflux Machine. Mol. Cell 30, 114–121 (2008).
39. Xu, Y. et al. Assembly and channel opening of outer membrane protein in tripartite drug efflux pumps of gram-negative bacteria. J. Biol. Chem. 287, 11740–11750 (2012).
40. Du, D., van Veen, H. W. & Luisi, B. F. Assembly and operation of bacterial tripartite multidrug efflux pumps. Trends Microbiol. 1–9 (2015). doi:10.1016/j.tim.2015.01.010
41. Zgurskaya, H. I., Krishnamoorthy, G., Ntreh, A. & Lu, S. Mechanism and function of the outer membrane channel TolC in multidrug resistance and physiology of enterobacteria. Front. Microbiol. 2, 1–13 (2011).
42. Masi, M., Duret, G., Delcour, A. H. & Misra, R. Folding and trimerization of signal sequence-less mature TolC in the cytoplasm of Escherichia coli. Microbiology 155, 1847–1857 (2009).
43. Koronakis, V., Sharff, a, Koronakis, E., Luisi, B. & Hughes, C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 405, 914–919 (2000).
44. Andersen, C. et al. Transition to the open state of the TolC periplasmic tunnel entrance. Proc. Natl.
Acad. Sci. U. S. A. 99, 11103–11108 (2002).
45. Bavro, V. N. et al. Assembly and Channel Opening in a Bacterial Drug Efflux Machine. Mol. Cell 30,
Chapter 1
17
114–121 (2008).
46. Benz, R., Maier, E. & Gentschev, I. TolC of Escherichia coli functions as an outer membrane channel. Zentralbl. Bakteriol. 278, 187–96 (1993).
47. Andersen, C., Hughes, C. & Koronakis, V. Electrophysiological behavior of the TolC channel-tunnel in planar lipid bilayers. J. Membr. Biol. 185, 83–92 (2002).
48. Delcour, A. H. Electrophysiology of bacteria. Annu. Rev. Microbiol. 67, 179–97 (2013).
49. Baslé, A., Iyer, R. & Delcour, A. H. Subconductance states in OmpF gating. Biochim. Biophys. Acta -
Biomembr. 1664, 100–107 (2004).
50. Andersen, C., Koronakis, E., Hughes, C. & Koronakis, V. An aspartate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44, 1131–1139 (2002).
51. Higgins, M. K. et al. Structure of the ligand-blocked periplasmic entrance of the bacterial multidrug efflux protein TolC. J. Mol. Biol. 342, 697–702 (2004).
52. Andersen, C., Koronakis, E., Hughes, C. & Koronakis, V. An aspartate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44, 1131–1139 (2002).
53. Opperman, T. J. & Nguyen, S. T. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol. 6, 421 (2015).
54. Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents
Chemother. 45, 105–16 (2001).
55. Lomovskaya, O. & Bostian, K. A. Practical applications and feasibility of efflux pump inhibitors in the clinic—A vision for applied use. Biochem. Pharmacol. 71, 910–918 (2006).
56. Nakayama, K. et al. MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg. Med. Chem. Lett. 13, 4201–4 (2003).
57. Yoshida, K. et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: Highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg. Med. Chem. 15, 7087–7097 (2007).
58. Sjuts, H. et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives. Proc. Natl. Acad. Sci. U. S. A. 113, 3509–14 (2016).
59. Abdali, N. et al. Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump. ACS Infect. Dis. 3, 89–98 (2017).
60. Opperman, T. J. et al. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob. Agents Chemother. 58, 722–33 (2014).
Chapter 1
18
19
Chapter 2
Biophysical characterization of the interaction
between E. coli TolC and hexaamminecobalt
The content of this chapter is partially based on the manuscript “Biophysical characterization
of E. coli TolC interaction with the known blocker hexaamminecobalt”
A. Gilardi, S.P. Bhamidimarri, M. Brönstrup, U. Bilitewski, R. K. R. Marreddy, K.M. Pos, L. Benier, P. Gribbon, M. Winterhalter, B. Windshügel
(Published in Biochimica et Biophysica Acta - General Subjects, Volume 1861, Issue 11, Part A, November 2017, Pages 2702-2709)
Individual Contribution
My contribution to this manuscript consisted in collaborating to design the study, performing
the biophysical and microbiological experiments and analyzing the output, as well as
participating in the composition of the manuscript.
Chapter 2
20
Abbreviations
Antimicrobial resistance (AMR); Resistance Nodulation and cell Division family (RND); Surface Plasmon Resonance (SPR); Minimal Inhibitory Concentration (MIC); E. coli Genetic Stock Center (CGSC); dimethyl sulfoxide (DMSO); Carbonyl cyanide m-chlorophenylhydrazone (CCCP); hexaamminecobalt (HC).
Chapter 2
21
2.1 Introduction
Antimicrobial resistance (AMR) in gram-positive and gram-negative bacteria has become one
of the major threats to the global health and it is expected that in the future AMR will lead to
increasing mortality of patients suffering from bacterial infections1,2. In particular gram-
negative bacteria have developed multiple ways to overcome the effect of antibiotics, including
the active export of antibiotics by means of efflux pumps3.
Bacterial efflux pumps are divided into six super families based on their functional and
phylogenetic classification3–5. In gram-negative bacteria, the ubiquitous transporters of the
Resistance Nodulation and cell Division (RND) super family are organized in tripartite
complexes6. These type of proteins comprise an inner membrane pump that confers specificity
for substrate(s) and transduces energy from the proton-motive force for the transport process7;
an outer membrane factor (OMF), which is considered to function as outer membrane channel
for the final extrusion of toxic molecules and a periplasmic adaptor protein (membrane fusion
protein, MFP), which forms a conduit through the periplasm by connecting the inner membrane
pump to the OMF8–10. In E. coli the most prevalent RND efflux system is composed of the inner
membrane transporter AcrB, the periplasmic adaptor AcrA and the OMF TolC. Several studies
have shown that the efflux system AcrAB-TolC plays a central role in efflux-mediated
resistance towards numerous toxic compounds, including antibiotics, bile salts, organic
solvents and detergents. Furthermore, it is involved in increasing minimal inhibitory
concentrations (MIC) of several antibiotics, e.g. erythromycin, fusidic acid or novobiocin, in
wild type strains compared to strains with deletions of efflux pump proteins3,11.
TolC has gained attention because of its involvement in the emergence of colistin-tolerant
bacterial strains12–14. The protein is a homotrimer which forms an extended channel with a
length of 140 Å15,16. It is anchored in the outer membrane (OM) with a 12-stranded β-barrel of
40 Å length and its α-helical barrel, composed of 12 α-helices, protrudes approximately 100 Å
into the periplasmic space. The periplasmic end of TolC interacts with AcrA10,17 for which a
variety of interaction models have been proposed and where the MFP has been highlighted for
its active role in inducing the opening of TolC18,19, based also on the elucidation of the
components interactions of different efflux pumps in E. coli20.
Unlike many other outer membrane proteins, possessing a constriction region located half way
through the barrel, TolC contains a constriction region located at the periplasmic tip (Fig. 2.1).
The internal diameter of TolC, 35 Å for most of its length, reduces to approximately 4 Å at the
Chapter 2
22
constriction region. A functionally relevant feature of the constriction region is the presence of
aspartate residues (Asp371 and Asp374) that are arranged in two rings and create an acidic
environment at the periplasmic end of the channel (Fig. 2.1). TolC is considered to adopt a
closed state when not part of the tripartite complex. This structural evidence is supported by the
relatively low electrophysiological conductance of a single channel (~100 pS)21,22, indicated by
the limited ionic current across this region. Also, structural studies on TolC mutants suggest an
iris-like opening model of the α-helical barrel23.
The biophysical properties of TolC have been investigated experimentally using artificial
bilayer systems21 that revealed three characteristics. Firstly, an asymmetric gating of the
channel, likely as a consequence of its asymmetric structure. Secondly, conductance properties
which are independent of the applied voltage gradient (≤120 mV) and, finally, the existence of
different conductance sub-states at elevated voltages (>100 mV)21. While different divalent and
trivalent monoatomic cations effectively inhibited the conductance of TolC, the trivalent cation
hexaamminecobalt is the only known inorganic small molecule compound with the same
effect22. X-ray crystal structures of TolC in complex with hexaamminecobalt show that the
periplasmic entrance of TolC is obstructed due to salt bridges between [NH3]+ groups of the
ligand and the residues Asp374 of each TolC monomer (Fig. 2.1)24.
This study aimed to further elucidate the basic biophysical characteristics of TolC and to better
understand the functional consequences of TolC’s interaction with hexaamminecobalt. This
improved understanding will support future studies of novel TolC modulating compounds that
have the potential to be developed into adjuvants as part of antibiotic therapies.
Chapter 2
23
Figure 2.1 X-ray crystal structure of TolC with bound hexaamminecobalt (PDB ID: 1TTQ). The secondary structure is represented with ribbons with each monomer colored differently. A transversal section of the periplasmic end shows the interactions of hexaamminecobalt with the two aspartate rings. Salt bridges are shown as grey dotted lines.
Chapter 2
24
2.2 Materials and methods
Protein expression and purification (SPR experiments): TolCWT and its TolCDADA mutant21,22,
carrying an his-tag construct, were expressed in E. coli C43(DE3)ΔacrAB and purified as
previously described17,25. All purification steps were performed at 4°C. The proteins were
eluted in a 10 ml buffer (Tris-HCl 20 mM, pH 7.5, NaCl 150 mM, imidazole 200 mM pH 8.0,
and 0.03 % DDM). TolC containing fraction was desalted (NAP-10, GE Healthcare) using
buffer containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.03 % DDM.
Expression and purification of TolCWT (single-channel measurements): an overnight pre-
culture of E. coli BL21(DE3)Omp8 containing pAX629 was inoculated into LB medium
containing chloramphenicol at OD 0.1. The cultures were grown overnight at 37°C, 200 rpm.
Cells were harvested by centrifugation at 6000 g for 20 min at 4°C and stored at -20°C until the
purification. For purification, a pellet from 1 L of culture was resuspended into lysis buffer
(20mM Tris-HCl pH 7.5, 5 mM MgCl2, protease inhibitor cocktail (Serva), 50 µg/ml RNAse A
and 5 µg/ml DNase I) and disrupted with 4 passages at 4000 psi in a French Press. After
removing the cell debris by 40 min of centrifugation at 3220 g and 4°C, a solution containing
0.5 % (w/v) sarkosyl (Sigma Aldrich) was added to the supernatant and incubated for 1 h at
4°C under gentle rotation, to solubilize the inner membrane. The outer membrane fraction was
pelleted by ultracentrifugation (1 h, 110,000 g at 4°C) and the pellet was solubilized in 10 ml
of 20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 3 % Octyl POE (Bachem) for 1 h at room
temperature on the wheel. The remaining insoluble material was separated by a second
ultracentrifugation (110,000 g, room temperature, 1 h) and the supernatant was concentrated 5
times with an Amicon concentration unit (cut off 50 kDa). TolC was then purified by anion
exchange chromatography with a MonoQ 5/50GL 1 ml (GE Healthcare). The protein was
eluted with a NaCl gradient (0 to 1 M) in buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl2). 15 µL
of the fractions were loaded on 12 % SDS PAGE gel for analysis after silver staining.
Single-channel conductance: Electrophysiological properties of TolC was monitored using an
Ionovation Compact (Ionovation). As described previously26,27, an artificial planar lipid bilayer
was formed across an aperture of ~120 μm diameter in a 25 μm thick Teflon foil separating the
cis and trans chambers filled with 1 M KCl pH 7.0. The chambers were connected to an
amplifier via Ag/AgCl electrodes with 2 M KCl salt bridges. Bilayer formation was carried out
by addition of 0.7-1 µl of DPhPC dissolved in n-decane, to the cis chamber (ground electrode)
and monitored optically by a CCD camera27. Following stable lipid bilayer formation
(capacitance >60 pF), TolCWT was added to the trans-chamber (live electrode) and the
Chapter 2
25
measurement started upon protein insertion (~100 pS). Hexaamminecobalt (III) chloride
(Sigma-Aldrich, powder) was solved in distilled water at 100 mM and diluted in 1 M KCl pH
7 for concentration-dependent measurements. Conductance data were acquired at a sampling
frequency of 1 kHz. Data were subjected to a low-pass-filter at 2 kHz and digitized using an
EPC 10 Patch Clamp Amplifier running Patchmaster software (HEKA). Electrophysiological
properties of individual inserted proteins were monitored under a range of applied voltages and
polarities. Conductance values [(G) = current (I)/voltage (V)] were exported to electronic
datasheets from the Patchmaster software. Power spectra and residence time (τ) analysis were
performed with Clampfit 10.6 (Molecular Devices).
In addition, we measured channel conductance properties on a classical bilayer apparatus with
an Axopatch 200B amplifier, as described elsewhere28. Briefly, traces were recorded at 10 kHz
filter and 50,000 sampling rate. Data was analysed by Clampfit program and plotted using
Prism software. Association rates and residence time of the substrate were calculated as
described elsewhere 29.
Antimicrobial and synergistic assay: Antibacterial activities were investigated over a 24 h
incubation time using a protocol adapted from30. The strains used were E. coli K12 BW25113
(E. coli K12), from CGSC and E. coli K12 JW5503-1 (E. coli ΔTolC), not expressing the outer
membrane protein TolC. Carbonyl cyanide m-chlorophenylhydrazone (CCCP), a known
inhibitor of the efflux pump31, was used as a positive control.
Hexaamminecobalt (III) chloride (Sigma-Aldrich, powder) was dissolved in distilled water at
100 mM, while CCCP (Sigma-Aldrich, powder) was dissolved in DMSO at 100 mM. Starting
from over-night pre-cultures in Tryptic Soy Broth pH 7.0 (TSB, Sigma-Aldrich), fresh working
cultures were prepared and incubated for 1-3 hours at 37°C, 160 rpm. Assays were performed
in half-area, clear 96-well plates, (Costar, #3697) with a total well volume of 100 µl. In parallel,
compound source plates with different concentrations of hexaamminecobalt and CCCP were
prepared. Compounds were transferred first to the assay plate (1 % v/v) followed by TSB
medium and 10 µl of cell cultures in exponential growth phase (OD600 ~0.07-0.1). The final
compound concentration range was 0-100 µM for hexaamminecobalt and 0-250 µM for CCCP.
Assay plates were incubated (37°C, 80 % humidity) up to 24 hours. To monitor bacterial
growth, the OD600 was measured every 2 hours from 0 hours to 6 hours and at 24 hours in a
multiplate reader (µQuant, Biotek). In synergistic assays, hexaamminecobalt and CCCP effects
were measured in the presence of sub-MIC concentrations of antibiotics (6.8 µM erythromycin
or 6 µM fusidic acid). Negative controls (only TSB medium, only bacterial culture) and positive
Chapter 2
26
controls (CCCP 0-250 µM) were included in each assay plate. CCCP stock was solved in
DMSO, so that test wells and control wells contained DMSO at 1 % v/v.
Surface Plasmon Resonance (SPR): Binding of hexaamminecobalt to TolC was determined
using a MASS-1 (Sierra Sensors GmbH). TolCWT and TolCDADA were immobilized using direct
amino coupling or a cross-linking protocol (ligand capture of the His-tagged protein to a NTA-
coated sensor and covalently immobilized by amino-coupling). TolC capture involved sensor
surface activation with NiSO4 buffer and protein injection, followed by coupling with
NHS/ECS and saturation of the sensor surface by ethanolamine. All experiments for binding
affinity determination were based on the injection of different analyte concentrations
(hexaamminecobalt, 0-100 µM in 1:3 dilution ratio) over the immobilized protein (ligand). In
the direct amino-coupling method TolC was immobilized on the sensor after dilution in acetate
buffer (pH 4), while for the NTA-capturing it was solved in immobilization buffer (150 mM
NaCl, 20 mM Hepes pH 7.5, 0.03 % DDM) and injected at a flow rate of 10 µl/min for 7
minutes, followed by 30 seconds of buffer washing (dissociation time). Hexaamminecobalt
titrations were prepared in running buffer (150 mM NaCl, 20 mM Tris-HCl pH 6, 0.03 %
DDM) and injected at a flow rate of 25 µl/min for 3 minutes, followed by 3 minutes of buffer
washing (dissociation time), to allow spontaneous dissociation of the analyte32. Data were
subjected to reference measurement subtraction to account for solvent effects and non-specific
interactions at the sensor surface using the Analyzer 3 (SierraSensors GmbH) software and
GraphPad Prism 7.
Chapter 2
27
2.3 Results and Discussion
2.3.1 Voltage-dependent TolC opening and asymmetric behavior
At first, we investigated the basal conductance of TolC in absence of any ligand. When inserted
into an artificial planar lipid bilayer, we measured a basal conductance of 89.1 ± 1.3 pS at
+100 mV and 106.5 ± 2.8 pS at 100 mV in 1 M KCl pH 7 (Fig. 2.2a). These results are in the
same range as values determined in a previous study21. At applied voltages ranging between
120 mV and +120 mV, TolC showed symmetric opening properties, as conductance values
were independent of polarity (Fig. 2.2a). Also this observation is in agreement with already
published data21,22. However, when we measured TolC conductance at higher voltages than
previously reported (>120 mV), we observed that TolC gating became voltage-dependent and
asymmetric (Fig. 2.2a-c). Voltage-dependent opening resulted in increased conductance at
increasing applied voltages. This suggests that the potential gradient induces channel opening,
possibly acting on the α-helices at the periplasmic site, which are considered to be the most
flexible region of the protein16,23. At these higher applied voltages (> ±140 mV), we also
observed asymmetric behavior with TolC gating more prominently at only one voltage polarity
(175 mV) and a strict dependence on the orientation of the protein within the artificial bilayer
(Fig. 2.2c). TolC orientation in artificial membranes has been already investigated by Andersen
et al.21, who observed channel insertion into the bilayer always with the β-barrel first.
Therefore, we expected the periplasmic domain to be localized at the trans side of the chamber
(Fig. A2.1). Furthermore, in agreement with the reported cation selectivity of TolC21,22, we
observed increased gating at negative potentials, which is associated with higher current of
potassium ions under these conditions.
Chapter 2
28
Figure 2.2 Single-channel conductance measurements in 1 M KCl pH 7.0: a) TolCWT conductance at applied voltages at alternative polarity, from ±10 to ±150 mV (each point is the resulting mean and SEM of 4 independent measurements); b) TolCWT conductance at ±25, ±100 and ±175 mV (each point is the resulting mean and SEM of 6 independent measurements); c) gating difference at high opposite polarities. Statistical differences were analyzed with Student’s t-test (* p < 0.05).
Chapter 2
29
2.3.2 Hexaamminecobalt blocks TolC opening
In a second step, we elucidated the interaction of hexaamminecobalt with TolC. At first, we
investigated the compound effect when added either on the cis (extracellular) or trans
(periplasmic) side. Ion current analysis of hexaamminecobalt added on the cis side at low and
medium applied voltages (100 mV to +100 mV) revealed similar voltage-dependent current
changes at all tested compound concentrations (0.05 µM to 10 µM, Fig. 2.3a-b) as observed in
the absence of compound. However, at 175 mV the ion current reduces at high (10 µM)
hexaamminecobalt concentration (Fig. 2.3b-c). The lack of changes in the mean current at low
applied voltages observed at these conditions could imply that hexaamminecobalt is not
interacting with TolC when is adopting the closed state, although the temporal resolution
restrictions of electrophysiological readouts do not allow for individual interaction events to be
discriminated under closed state conditions or small charged molecules. It seems then that
hexaamminecobalt requires a stronger electric potential to reach the periplasmic tip when added
at the extracellular side. Interestingly, the concentration-dependent current decrease at 175
mV was not detectable at +175 mV, even though fluctuations were still present. These
differences are consistent with TolC cation-selectivity, as positively charged
hexaamminecobalt molecules are pulled from the cis to the trans side once negative potentials
are applied. This effect is potentiated by the higher concentration of the compound on the
extracellular side.
Analysis of the current versus time traces at an applied voltage of 175 mV revealed that the
increased gating induced by the applied potential is reduced by addition of hexaamminecobalt
to the KCl solution of the extracellular side. This effect leads to a shift of the basal current
signal (Fig. 2.4a) and a lower number of negative spikes (Fig. 2.4b), which indicates a decrease
in the number of rapid opening events.
In a second step, we investigated the effect of hexaamminecobalt on TolC, when added on the
periplasmic side of the channel (Fig. 2.5). At 0.25 µM compound concentration we observed
an interaction with TolC (Fig. 2.5c-d) on the periplasmic side at ±100 mV compared to the
absence of hexaamminecobalt (Fig. 2.5a-b). Only at negative voltages (100 mV, Fig. 2.5d)
well-resolved TolC blockages were evident.
Chapter 2
30
Figure 2.3 a) I/V plot of single-channel measurements for TolCWT in absence and presence of hexaamminecobalt; b) Voltage applied ±10-60 mV and ±25, ±100, ±175 mV, in 1 M KCl pH 7; c) detail of the current fluctuation at ±175 mV, columns show means and SEM of 3 independent measurements. Statistical significant differences
between 175 and +175 mV at 10 µM were analysed by Student’s t-test (* p < 0.05).
Chapter 2
31
Figure 2.4 Representative current (I) vs time traces of single-channel measurements with a) TolCWT alone and in
b) presence of hexaamminecobalt at 10 µM and applied voltage of 175 mV in 1 M KCl pH 7; Inset: trace detail of 200 ms for each condition.
2.3.3 Binding affinity of hexaamminecobalt
Single-channel conductance measurements
In order to determine the binding affinity of hexaamminecobalt for TolC, single channel
conductance measurements were carried out. Our results show that hexaamminecobalt
efficiently blocks TolC when added on the periplasmic side (Fig. 2.5c-d) even at low applied
voltages. To quantify the kinetic interaction between compound and channel, traces were
filtered at 1 kHz to determine the association rate (kon) and residence time (τ). The association
rate was obtained by the number of binding events divided by the concentration, resulting in
12.8 ± 0.9 x 107 M-1 s-1 while the residence time was calculated by the exponential fit of the
dwell-time histogram, resulting in τ = 6.1 ± 0.7 ms (Fig. 2.5e). Utilizing these values we
determined the binding affinity K = kon/koff = kon / (1/ τ) = 7.5 µM.
Based on the interaction observed in Fig. 2.4, with hexaamminecobalt added on the
extracellular side of TolC, we analyzed conductance data obtained at 175 mV (Fig. A2.3a).
The half-saturation constant (ks = 1/K) was derived by fitting the data to the equation (Gmax –
Gc)/Gmax = K x c / (1 + K x c), where Gmax and Gc are the membrane conductance values before
Chapter 2
32
and after addition of the interacting compound at concentration c, already described
previously22 and shown in Fig. A2.3a.
The inhibition of channel conductance by hexaamminecobalt was quantified by means of an
IC50 determination (Fig. A2.3b). The IC50 was derived from plotting the conductance signal
against the compound concentration to produce a dose-response curve, according to Y = 100 /
(1 + X / IC50). To normalize across independent recordings, the conductance measured at
175 mV was defined as maximum opening (induced open state) of the channel in these specific
experimental conditions. The mean conductance measured between 10-100 mV was considered
as minimum opening (closed-state).
Upon adding increasing concentrations of hexaamminecobalt on the cis side of the chamber,
the ionic current decreased, resulting in a ks = 1.42 ± 0.4 x 106 M and an IC50 = 0.6 ± 0.3 x 106
M when measuring the channel conductance at 175 mV. To summarize, the derived binding
affinity are expressed in our analysis with K (derived from hexaamminecobalt addition to the
periplasmic side), ks (resulting from the hexaamminecobalt addition to the extracellular side)
and they all show comparable values.
Surface Plasmon Resonance (SPR)
We employed SPR for monitoring affinities and kinetics of hexaamminecobalt (analyte) to
immobilized TolC (ligand). In contrast to the electrophysiology studies described before, no
external forces are applied to TolC, which in these conditions is likely not to be affected by
significant conformational changes due the absence of electric fields applied.
The sensorgram in Fig. 2.6a shows a concentration-dependent binding of hexaamminecobalt to
TolCWT, while we did not observe any binding to TolCDADA (Asp371 and Asp374 mutated into
alanine22,33) (Fig. 2.6b). For TolCWT hexaamminecobalt revealed a rapid association and
dissociation (Fig. 2.6a). These fast events prevented the quantification of the kon and koff rates
by means of standard SPR kinetic analyses, which typically employ a 1:1 Langmuir binding
model. The dissociation constant (Kd) was calculated based upon a steady-state, or equilibrium
analysis34. The steady-state analysis (Fig. 2.6c) shows that binding of hexaamminecobalt to
TolCWT is concentration-dependent with a Kd of 0.74 ± 0.5 µM.
Chapter 2
33
Figure 2.5 Single-channel conductance measurements of TolCWT at a) + 100 mV, b) 100 mV and with 0.25 µM
hexaamminecobalt c) + 100 mV, d) 100 mV, in 1 M KCl, pH 7; e) histogram distribution of dwell time derived from the traces analysis.
Chapter 2
34
Figure 2.6 a) Sensorgram of hexaamminecobalt injected at various concentrations over immobilized TolCWT and b) TolCDADA; c) equilibrium binding analysis of hexaamminecobalt injected over immobilized TolCWT and TolCDADA. Values and error bars in c) represent the mean and SEM of 6 independent experiments.
Chapter 2
35
2.3.4 Hexaamminecobalt does not possess antimicrobial activity in E. coli strains
In order to investigate whether TolC blockage by hexaamminecobalt either inhibits bacterial
growth or reveals any synergistic effect with approved antibiotics, the compound was tested in
E. coli cultures expressing a functional (E. coli K12) or non-functional efflux pump (E.
coli ΔTolC). Bacterial growth was monitored at different time points and at different
concentrations of hexaamminecobalt or of the known efflux pump inhibitor CCCP. Since CCCP
was dissolved in DMSO, tolerance of the bacterial cultures was determined for both strains at
different DMSO concentrations (% v/v) and incubation times (Fig. A2.4). For both strains we
did not observe any bacterial growth inhibition by hexaamminecobalt alone at concentrations
up to 100 µM (Fig. 2.7a-b, Fig. A2.5). In contrast, CCCP showed antimicrobial activity in E.
coli ΔTolC already at low compound concentrations.
In addition, we tested hexaamminecobalt and CCCP for any synergistic effect with antibiotics
erythromycin and fusidic acid which are known substrates of the AcrAB-TolC efflux pump35.
In presence of sub-MIC concentrations of both antibiotics we observed no synergistic effects
with hexaamminecobalt (Fig. 2.7c-f) while CCCP improved the efficacy of erythromycin and
fusidic acid.
Our results show that hexaamminecobalt does not act as efflux pump inhibitor in bacterial
whole-cell environment at ≤100 µM. This might be related to the permeability of
hexaamminecobalt or due to its small size, which might not be able to control the AcrAB-
mediated TolC opening. Furthermore, evidence of significant depletion of TolC in vivo was
already proved not too affect considerably the efflux activity of E. coli36.
Chapter 2
36
Figure 2.7 a) Antimicrobial activity of hexaamminecobalt and CCCP tested in E. coli K12 and b) E. coli ΔTolC
cultures; c) evaluation of synergistic effects of either hexaamminecobalt or CCCP in presence of 6.5 µM
erythromycin in E. coli K12 and d) E. coli ΔTolC; e) evaluation of synergistic effects of either hexaamminecobalt
or CCCP in presence of 6 µM fusidic acid in E. coli K12 and f) E. coli ΔTolC. Values and error bars represent the
mean and SD (n=2), data detection at 24 hours incubation.
Chapter 2
37
2.4 Conclusion
TolC represents a potentially attractive target for inhibiting efflux pump function in gram-
negative bacteria. Therefore, a detailed understanding of TolC function and the development of
quantitative methods to measure binding and modulation by small molecules are of great
interest. Using a variety of biophysical methods, we investigated the interaction of
hexaamminecobalt with E. coli TolC.
Our electrophysiology measurements revealed that TolC shows asymmetric conductance
behavior at ≥150 mV and different polarities. The implications for the conformational state of
TolC under these conditions are still unclear, but it could be the effect of the electric field on
mobile ions, which in turn leads to channel opening. Alternatively, the electric field could have
a direct influence on the charged residues of the channel. Based on the analysis of dose-response
single-channel experiments we were able to reveal blockage events that confirmed and explored
in a deeper way the known interaction of hexaamminecobalt. At an applied voltage of 175 mV,
we observed a concentration-dependent decrease in current in presence of hexaamminecobalt.
At 10 µM concentration of this positively charged molecule, we observed a clear shift in the
current baseline and a decrease in the frequency of negative spikes, representative of rapid
channel gating events. Furthermore we performed a quantitative analysis, calculating
comparable binding values of the molecule added on the cis-side (extracellular side) with IC50
(0.6 ± 0.3 µM) and ks (1.42 ± 0.4 µM) values in the micromolar range.
Analysis of single-channel traces with hexaamminecobalt added on the periplasmic side of
TolC showed affinity also at low polarities. This observations led to the calculation of on- and
off-rates for hexaamminecobalt, with a kon = 12.8 ± 0.9 x 107 M-1s-1 and a corresponding
residence time, (τ) of 6.1 ± 0.7 ms. These findings are consistent with the rapid association and
dissociation rates observed in SPR experiments, which did not allow for direct determination
of kon and koff.
Based on the analysis of the steady-state from SPR experiment we could calculate the
dissociation constant (Kd) of hexaamminecobalt for TolC of 0.74 ± 0.5 µM, which is
comparable to the ks and K determined through single-channel electrophysiology measurement
(reported above). These findings support the complementarity of the two biophysical methods,
including insights on the different affinity of the hexaamminecobalt interacting with TolC from
the periplasmic or from the extracellular side.
Chapter 2
38
Cellular tests are valuable to determine possible toxicity of the compounds in bacterial cultures
and to detect synergistic effects with antibiotics. For hexaamminecobalt we could not detect
any intrinsic antimicrobial activity or synergistic effect in presence of standard antibiotics,
leaving open questions on the action of this small molecule in in vivo conditions.
To conclude, with this study we have described the application of a qualitative and quantitative
biophysical analysis for the characterization of TolC using hexaamminecobalt as a tool
compound, enriching the literature on this regard. These findings will support future
investigations seeking to identify compounds with more “drug-like” characteristics which
might be useful in an adjuvant role and help increase the concentration and therefore efficacy
of antibiotics within pathogenic gram-negative bacteria.
Chapter 2
39
References:
1. Neill, J. O. ’. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations The Review on Antimicrobial Resistance Chaired. (2014).
2. WHO | Antibiotic resistance. WHO (2016).
3. Li, X. Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
4. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453, 254–267 (2014).
5. Hassan, K. A., Liu, Q., Henderson, P. J. F. & Paulsen, I. T. Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems. MBio 6, e01982-14 (2015).
6. Tseng, T. T. et al. The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. J. Mol. Microbiol. Biotechnol. 1, 107–25 (1999).
7. Vaccaro, L., Scott, K. a & Sansom, M. S. P. Gating at both ends and breathing in the middle: conformational dynamics of TolC. Biophys. J. 95, 5681–5691 (2008).
8. Muller, R. T. & Pos, K. M. The assembly and disassembly of the AcrAB-TolC three-component multidrug efflux pump. Biol. Chem. 396, 1083–1089 (2015).
9. Du, D. et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature 509, 512–5 (2014).
10. Du, D., van Veen, H. W. & Luisi, B. F. Assembly and operation of bacterial tripartite multidrug efflux pumps. Trends Microbiol. 1–9 (2015). doi:10.1016/j.tim.2015.01.010
11. Ge, Q., Yamadah, Y. & Zgurskaya, E. The C-terminal domain of AcrA is essential for the assembly and function of the multidrug efflux pump AcrAB-TolC. J. Bacteriol. 191, 4365–4371 (2009).
12. Sulavik, M. C. et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob. Agents Chemother. 45, 1126–36 (2001).
13. Morona, R., Manning, P. A. & Reeves, P. Identification and Characterization of the ToIC Protein, an Outer Membrane Protein from Escherichia coli. J. Bacteriol. 153, 693–699 (1983).
14. Paulsen, I. T., Park, J. H., Choi, P. S. & Saier, M. H. A family of Gram-negative bacterial outer membrane factors that function in the export of proteins, carbohydrates, drugs and heavy metals from Gram-negative bacteria. FEMS Microbiol. Lett. 156, 1–8 (2006).
15. Koronakis, V., Li, J., Koronakis, E. & Stauffer, K. Structure of TolC, the outer membrane component of the bacterial type I efflux system, derived from two-dimensional crystals. Mol. Microbiol. 23, 617–626 (1997).
16. Koronakis V Sharff A, K. E. et al. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 405, 914–919 (2000).
17. Daury, L. et al. Tripartite assembly of RND multidrug efflux pumps. Nat. Commun. 7, 10731 (2016).
18. Jeong, H. et al. Pseudoatomic Structure of the Tripartite Multidrug Efflux Pump AcrAB-TolC Reveals the Intermeshing Cogwheel-like Interaction between AcrA and TolC. Structure 24, 272–276 (2016).
19. Wang, Z. et al. An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump. Elife 6, 759–796 (2017).
20. Fitzpatrick, A. W. P. et al. Structure of the MacAB–TolC ABC-type tripartite multidrug efflux pump. Nat. Microbiol. 2, 17070 (2017).
21. Andersen, C., Hughes, C. & Koronakis, V. Electrophysiological behavior of the TolC channel-tunnel in planar lipid bilayers. J. Membr. Biol. 185, 83–92 (2002).
Chapter 2
40
22. Andersen, C., Koronakis, E., Hughes, C. & Koronakis, V. An aspartate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44, 1131–1139 (2002).
23. Andersen, C. et al. Transition to the open state of the TolC periplasmic tunnel entrance. Proc. Natl.
Acad. Sci. U. S. A. 99, 11103–11108 (2002).
24. Higgins, M. K. et al. Structure of the ligand-blocked periplasmic entrance of the bacterial multidrug efflux protein TolC. J. Mol. Biol. 342, 697–702 (2004).
25. Pos, K. M. & Diederichs, K. Purification, crystallization and preliminary diffraction studies of AcrB, an inner-membrane multi-drug efflux protein. Acta Crystallogr. Sect. D Biol. Crystallogr. 58, 1865–1867 (2002).
26. Mueller, P., Rudin, D. O., Ti Tien, H. & Wescott, W. C. Reconstitution of Cell Membrane Structure in vitro and its Transformation into an Excitable System. Nature 194, 979–980 (1962).
27. Okazaki, M. et al. VDAC3 gating is activated by suppression of disulfide-bond formation between the N-terminal region and the bottom of the pore. Biochim. Biophys. Acta - Biomembr. 1848, 3188–3196 (2015).
28. Schwarz, G., Danelon, C. & Winterhalter, M. On Translocation through a Membrane Channel via an Internal Binding Site: Kinetics and Voltage Dependence. Biophys. J. 84, 2990–2998 (2003).
29. Bhamidimarri, S. P., Prajapati, J. D., van den Berg, B., Winterhalter, M. & Kleinekathöfer, U. Role of Electroosmosis in the Permeation of Neutral Molecules: CymA and Cyclodextrin as an Example. Biophys. J. 110, 600–611 (2016).
30. Balouiri, M., Sadiki, M. & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity : A review Author ’ s Accepted Manuscript. J. Pharm. Anal. 6, 71–79 (2015).
31. Levy, S. B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36, 695–703 (1992).
32. Tikhonova, E. B., Dastidar, V., Rybenkov, V. V & Zgurskaya, H. I. Kinetic control of TolC recruitment by multidrug efflux complexes. Proc. Natl. Acad. Sci. U. S. A. 106, 16416–16421 (2009).
33. Koronakis, V., Eswaran, J. & Hughes, C. Structure and function of TolC: the bacterial exit duct for proteins and drugs. Annu. Rev. Biochem. 73, 467–489 (2004).
34. Myszka, D. G., Jonsen, M. D. & Graves, B. J. Equilibrium Analysis of High Affinity Interactions Using BIACORE. Anal. Biochem. 265, 326–330 (1998).
35. Nikaido, H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178, 5853–5859 (1996).
36. Krishnamoorthy, G., Tikhonova, E. B., Dhamdhere, G. & Zgurskaya, H. I. On the role of TolC in multidrug efflux: The function and assembly of AcrAB-TolC tolerate significant depletion of intracellular TolC protein. Mol. Microbiol. 87, 982–997 (2013).
Chapter 2
41
Annex Chapter 2 (A2)
Figure A2.1 Schematic representation of TolC orientation when inserted in an artificial bilayer (left side addition).
Figure A2.2 I/V plot of single-channel measurements of TolCWT. Voltage applied ±10-60 mV, in 1 M KCl pH 7.
Chapter 2
42
Figure A2.3 Hexaamminecobalt titration in single-channel conductance measurements of TolCWT, voltage applied
175 mV, buffer 1 M KCl, pH 7: a) Half-saturation constant derivation and b) determination of the concentration at 50 % of the conductance inhibition (IC50). Each point is the resulting mean of 3 independent measurements.
Figure A2.4 DMSO tolerance of E. coli K12 and K12-ΔTolC cultures at different incubation time-points.
Chapter 2
43
Figure A2.5. Antimicrobial activity of hexaamminecobalt and CCCP titrations in E. coli K12 and E. coli ΔTolC cultures (6h incubation).
Chapter 2
44
45
Chapter 3
Identification of small molecules binding E. coli TolC
through in silico studies and their biophysical
validation
The content of this chapter is partially based on the manuscript “Structure-Based discovery
of small organic molecules binding to and blocking TolC”
A. Gilardi1,2, U. Bilitewski3, M. Brönstrup3, K.M. Pos4, A. Razeto1, E. Sassetti1, M. Winterhalter2, P. Gribbon1, B. Windshügel1
1Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany
2Jacobs University Bremen, Campus Ring 1, 28759 Bremen, Germany
3Helmholtz Centre for Infection Research and German Center for Infection Research (DZIF), Inhoffenstraße 7, 38124 Braunschweig, Germany
4Goethe University Frankfurt, Institute of Biochemistry, Max-von-Laue-Straße 9, 60438 Frankfurt, Germany
(Manuscript submitted, in revision)
Individual Contribution
My contribution to this manuscript consisted in collaborating to design the study, performing
the virtual screening and docking studies, biophysical and microbiological experiments and
analyzing the output, as well as participating in the composition of the manuscript.
Chapter 3
46
Chapter 3
47
3.1 Introduction
Elevated efflux from bacteria is an established mechanism of resistance to toxic substances for
the microorganism itself. In particular in gram-negative bacteria, efflux pumps (EPs) are one
of the main actors in the resistance machinery. Efflux pumps are mainly tripartite complexes
localized and embedded in the plasma membrane of the bacterium and whose function is to
recognize noxious agents, which have penetrated the intracellular space of the bacteria, and
extrude them as rapidly and efficiently as possible before the compounds can modulate their
primary molecular targets1,2.
The tripartite complex AcrAB-TolC is an E. coli efflux pump and, as well as its homolog
MexAB-OprM in P. aeruginosa, is intensively studied due to its major contribution to
antibiotic resistance in clinical settings3. Several antibiotics have been proved to be substrates
for AcrAB-TolC, including fluoroquinolones, novobiocin, erythromycin, fusidic acid4.
Furthermore, certain substrates, such as tetracyclines, are associated with the upregulation of
efflux pumps expression2.
Identifying molecules able to block efflux pumps action, defined as efflux pump inhibitors
(EPIs), is an interesting yet challenging goal, given their potential in reviving the anti-microbial
activity of existing antibiotics for which the clinical utility has been compromised by their rapid
efflux by resistant bacteria5. Up to now, several studies focused on finding molecules which
target efflux pumps in P. aeruginosa (MexAB-OprM) and E. coli (AcrAB-TolC), addressing
specifically the inner membrane proteins (IM) AcrB or MexB, and which succeeded in
discovering relevant molecules, such as MC-2017110 (PAβN)6,7 and MBX23198. Recently, a
study was published for the identification of EPIs targeting AcrA9, reflecting the key role of
periplasmic adaptors in efflux pumps. An important point to take in consideration during the
early stage development of EPIs and in general adjuvants for antimicrobial therapies is to
ensure specificity, to avoid off-target selectivity, such as for mammalian efflux systems. P-
glycoproteins (P-gp) mediate the efflux of antibiotics, drugs and chemotherapeutics from
mammalian cells, using ATP hydrolysis10. They are highly expressed in different organs and
tissues important for adsorption, elimination and distribution of drugs, controlling their
pharmacokinetics, efficacy and safety11.
The important role of TolC in the structure and function of the outer membrane (OM) of E. coli
has been known for at least 30 years12, after it was established that TolC and its homologs in
other gram-negative bacteria enable transport of various toxic molecules across the OM13.
Chapter 3
48
TolC is a homotrimeric protein which forms an extended channel with a length of 140 Å14. It
is anchored in the OM with a 12-stranded β-barrel of 40 Å length and its α-helical barrel,
composed of 12 α-helices, protrudes ~100 Å into the periplasmic space. The periplasmic end
of TolC interacts with AcrA15,16 and a variety of interaction models have been proposed17.
TolC plays an important role in efflux of antibiotics and therefore represents an interesting
target for pharmaceutical intervention. In the past TolC has been already object of study for the
identification of molecules that could modulate its opening, in particular targeting its
periplasmic end and the acidic pocket in this region, like for example Hexaamminecobalt
(HC)14,18. Hexaamminecobalt, a positively charged small inorganic compound (~ 260 Da) has
been so far one of few molecules, together with other cations, to have been structurally and
biophysically characterized for its capacity to bind TolC and induce blockage events in single-
channel measurements18,19. Hexaamminecobalt has a Kd ~ 0.7 µM for TolCWT (presented in
chapter 2) and although it has been shown not to have any synergistic effect in presence of
antibiotics20, its specificity and binding mode represent a good starting point for the
identification and development of molecules with similar chemical properties, e.g. presence of
positively charged groups. So far, the only few known efflux pump inhibitors for E. coli target
AcrB5,8 or AcrA9.
In this chapter, the discovery of the first small organic molecules identified is reported, starting
from a structure-based in silico cascade, to bind and block TolC. Based on a virtual screening
campaign several potential TolC-binding compounds were identified and validated using SPR
and electrophysiology measurements (flow chart of the process is summarized in Fig. 3.1).
These may serve as starting points for the future development of TolC inhibitors effectively
blocking efflux of antibiotics.
Chapter 3
49
3.2 Methods
Molecular Modeling: a focused small molecule library was generated based on the Clean Leads
and Drug-like subset of the ZINC21 library using MOE (version 2013.08, Chemical Computing
Group Inc., Montreal, Canada). Only molecules possessing at least one -(NH3)+ group, in order
to consider the main interaction of hexaamminecobalt with TolC, and following Lipinski’s
Rule-Of-Five22 were considered. Selected molecules for the database were then minimized to
obtain an optimized 3D conformation.
The X-ray crystal structure of TolC in complex with hexaamminecobalt (PDB ID: 1TQQ) was
employed for the virtual screening campaign. The structure was prepared (protonation,
orientations of Asn, Gln and His side chains) using MOE and energy minimised using the
Tripos force field in SYBYL-X 2.1 (Certara Inc., St. Louis). Molecular docking was performed
using GOLD version 5.4.1 (Cambridge Crystallographic Data Centre, Cambridge, UK) and the
ChemPLP scoring function. For each compound 10 docking runs were carried out. The early
termination function was switched off and pyramidal nitrogens were allowed to flip. The
docking site was defined by a 15 Å radius around the coordinates of hexaamminecobalt
positioned in the co-crystal structure.
The dataset was ranked according to the Ligand Efficiency (LE). This value is resulting from
the normalization of the Fitness Score calculated from the docking by the number of heavy
atoms present in the ligand structure, for a comparable and reproducible evaluation23,24: LE =
Fitness Score / n. heavy atoms.
The virtual hit set was expanded by a similarity search within MOE for each of the 12
compounds emerging from the virtual screen.
Analogue identification search: a structure-based search for analogues of the compounds
identified from the virtual screening was performed using MOE (Chemical Computing Group).
The calculation was performed on the ZINC Clean Drug-Like subset in Molecular ACCess
System (MACCS) structural keys. For each of the original 12 compounds an independent
search was performed, using a threshold of 0.75 in the Tanimoto index25.
Protein expression and purification: TolCWT and TolCDADA (Asp371-374 mutated in alanines)26,
carrying an his-tag construct, were expressed in E. coli C43(DE3)ΔacrAB and purified as
described elsewhere27,16 (and in Chapter 2).
Chapter 3
50
TolCWT for single-channel measurements was not carrying tag constructs and was expressed
and purified according to the following protocol. An overnight pre-culture of E. coli
BL21(DE3)Omp8 containing pAX629 was inoculated into LB medium containing
chloramphenicol at OD 0.1. The cultures were grown overnight at 37°C, 200 rpm. Cells were
harvested by centrifugation at 6000 g for 20 min at 4 °C and stored at -20 °C until the
purification. For purification, a pellet from 1 L of culture was re-suspended into lysis buffer
(20mM Tris-HCl pH 7.5, 5 mM MgCl2, protease inhibitor cocktail (Serva), 50 µg/ml RNAse A
and 5 µg/ml DNase I) and disrupted with 4 passages at 4000 psi in a French Press. After
removing the cell debris by 40 min of centrifugation at 3220 g, 4 °C, a solution containing
0.5 % (w/v) sarkosyl (Sigma Aldrich) was added to the supernatant and incubated for 1 h at
4 °C under gentle rotation, to solubilize the inner membrane. The outer membrane fraction was
pelleted by ultracentrifugation (1 h, 110,000 g at 4 °C) and the pellet was solubilized in 10 ml
of 20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 3 % Octyl POE (Bachem) for 1 h at room
temperature on the wheel. The remaining insoluble material was separated by a second
ultracentrifugation (110,000 g, room temperature, 1 h) and the supernatant was concentrated 5
times with an Amicon concentration unit (cut off 50 kDa). TolC was then purified by anion
exchange chromatography with a MonoQ 5/50GL 1 ml (GE Healthcare). The protein was
eluted with a NaCl gradient (0 to 1 M) in buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl2). 15 µL
of the fractions were loaded on 12 % SDS PAGE gel for analysis after silver staining.
Single-channel conductance: Electrophysiological properties of TolC were monitored
(Compact Ionovation)28. As described previously29, an artificial planar lipid bilayer was formed
across an aperture of ~120 μm diameter in a 25 μm thick Teflon foil separating the cis- and
trans-chambers filled with the buffer (1 M KCl pH 7.0). The chambers were connected to an
amplifier via Ag/AgCl electrodes with 2 M KCl salt bridges. Bilayer formation was carried out
by addition of 0.7-1 uL of DPhDP dissolved in n-decane, to the cis-chamber (ground electrode)
and monitored optically by a CCD camera30. Following stable lipid bilayer formation
(capacitance > 60 pF), TolCWT was added to the trans-chamber (live electrode) and the
measurement started upon protein insertion (~100 pS). The compounds tested were solve in
DMSO and diluted in 1 M KCl pH 7.0 with a dilution factor of 1:1000, in order to limit solvent
effects. Further dilutions were then applied directly in the cis-side chamber, according to the
final concentration to test. Conductance data were acquired at a sampling frequency of 1 kHz.
Data were subjected to a low-pass-filter at 2 kHz, and digitized using an EPC 10 Patch Clamp
Amplifier running Patchmaster software (HEKA). Electrophysiological properties of
Chapter 3
51
individual inserted proteins were monitored under a range of applied voltages and polarities.
Conductance values [(G) = current (I)/voltage (V)] were exported to electronic datasheets from
the Patchmaster software, while analysis of the recorded traces was performed with Clampfit
10.6 (Molecular Device).
Antimicrobial and synergistic assay: the potential for antibacterial activity by
hexaamminecobalt was investigated for bacterial cultures over a 24 h incubation time using a
protocol adapted from31. The strains used were Escherichia coli K12 BW25113 (E. coli K12),
from CGSC and Escherichia coli K12 JW5503-1 (E. coli ΔTolC), not expressing the outer
membrane protein TolC. CCCP (carbonyl cyanide m-chlorophenylhydrazone), a known efflux
pump inhibitor32, was used as a positive control.
Hexaamminecobalt and CCCP compound source plates were prepared in dose-response
format. Starting from over-night pre-cultures in Tryptic Soy Broth pH 7.0 (TSB, Sigma-
Aldrich), fresh working cultures were prepared and incubated for 1-3 hours at 37 °C, 160 rpm.
Assays were performed in half-area, clear 96-well plates, (Costar, #3697) for a total well
volume of 100 µL. Compounds were transferred first to the assay plate (1 % v/v) followed by
TSB medium and 10 µL of cell cultures in exponential growth phase (OD600 ~ 0.07-0.1). The
final compound concentration range was 0-100 µM for compounds 1 to 33 and 0-250 µM for
CCCP. Assay plates were incubated (37°C, 80% humidity) up to 24 hours. To monitor bacterial
growth, the OD600 was measured every 2 hours from time 0 to 6 hours and at 24 hours in a
multiplate reader (µQuant, Biotek). In synergistic assays, hexaamminecobalt and CCCP effect
was measured in the presence of sub-MIC concentrations of antibiotics (6.8 µM Erythromycin
or 6 µM fusidic acid). Negative controls (only TSB medium, only bacterial culture) and
positive controls (CCCP 0-250 µM) were included in each assay plate. CCCP and compounds
dry stocks were solved in DMSO, so that test wells and control wells contained DMSO at 1 %
v/v.
Surface Plasmon Resonance (SPR): Binding of hexaamminecobalt to TolC was determined
using a MASS-1 (Sierra Sensors GmbH). TolCWT and TolCDADA were immobilized using direct
amino coupling or a cross-linking protocol (ligand capture of the His-tagged protein to a NTA-
coated sensor and covalent-immobilized through amino-coupling). TolC capture involved
sensor surface activation with NiSO4 buffer and protein injection, followed by coupling with
NHS/ECS and saturation of the sensor surface by ethanolamine. All experiments for binding
affinity determination were based on the injection of different analyte concentrations
Chapter 3
52
(hexaamminecobalt, 0-100 µM in 1:3 dilution ratio) over the immobilized protein (ligand). In
the direct amino-coupling method TolC was immobilized on the sensor after dilution in acetate
buffer (pH 4), while for the NTA-capturing it was solved in immobilization buffer (150 mM
NaCl, 20 mM Hepes pH 7.5, 0.03 % DDM) and injected at a flow rate of 10 µl/min for 7
minutes, followed by 30 seconds of buffer washing (dissociation time). Compound titrations
were prepared in running buffer (150 mM NaCl, 20 mM Tris-HCl pH 6, 0.03 % DDM) and
injected at a flow rate of 25 µl/min for 3 minutes, followed by 3 minutes of buffer washing
(dissociation time), to allow spontaneous dissociation of the analyte. To control for non-
specific interactions and solvent effects, signals were subjected to reference channel
subtraction, bulk-shift correction, DMSO calibration and further analysis with Analyzer 3
(SierraSensors GmbH) and GraphPad Prism 7.
Chapter 3
53
3.3 Results
3.3.1 Hit identification and validation
In order to identify TolC inhibitors a structure-based virtual screening campaign was conducted
using the X-ray crystal structure of TolC co-crystallized with the inorganic compound
hexaamminecobalt (PDB ID: 1TQQ).
Based on the ZINC library a focused small molecule library was generated containing lead-
like and drug-like compounds with at least one positively charged primary amine. The latter
criterion was defined based on the known interaction of hexaamminecobalt, containing six
positively charged primary amines. Altogether approximately 500,000 compounds were
selected and docked into the prepared X-ray crystal structure using GOLD with the built-in
ChemPLP scoring function. The 5,000 top-scored compounds were additionally re-docked
using the built-in GoldScore scoring function. The 500 top-scored compounds were visually
inspected for their binding modes and 12 compounds were selected for experimental validation.
In addition, a similarity search was conducted for all compounds, which gave a resulting
selection of 21 compounds, leading to a final set of 33 compounds to be experimental validated
(Table A3.1).
All virtual hits were tested for TolC binding using Surface Plasmon Resonance (SPR). At first
all compounds were tested at 10 µM concentration to assess their binding to the immobilized
wild type protein (TolCWT) and an Asp371/Asp374 double alanine mutant (TolCDADA).
Of the 33 tested compounds, eight of them (compounds 1, 8, 12, 13, 18, 25, 39 and 33) bound
to TolCWT showing RU values between 40 and 100 %, but only three of them (compound 8, 12
and 33) proved to be selective for the targeted pocket in TolCWT, having a relative binding
response to TolCDADA < 20 %. These compounds were therefore selected for further
characterization.
Interestingly, a group of compounds (e.g. compound 5) showed a relative binding response >
100 %, which could suggest the presence of different binding sites and that will be separately
discussed in the next paragraphs.
Chapter 3
54
Figure 3.1 Virtual screening workflow
Chapter 3
55
Figure 3.2 SPR screening: binding signal of compounds to TolCWT (purple bars) and TolCDADA (orange bars);
each screening started and ended with an injection of the positive control (HC, hexaamminecobalt) at 10 µM. The
grey dotted lines delimit the selection area for TolCWT (between 40 % and 100 % of the normalized binding
signal), while the orange dotted line represents the limit of binding response (20%) for TolCDADA. The compounds
with binding values included in the purple area for TolCWT and below the orange threshold for TolCDADA are
considered selective hits. The relative RU (%) is calculated by normalizing the raw SPR signal (RU) to the
theoretical Rmax (based on immobilization level of the ligand and on the molecular masses of ligand and analyte,
i.e. immobilized protein and compound injected). A value of 100 % represents the Rmax, calculated as maximum
signal arising from a 1:1 binding between ligand (TolCWT or TolCDADA) and analyte (compounds), while a
response of 0 % indicates no analyte binding. Values are representative of the mean ± SEM (TolCWT n=4,
TolCDADA n=2).
Chapter 3
56
3.3.2 Biophysical Hit characterization.
At first, kinetic and steady-state (or equilibrium) analysis was performed for the three selected
compounds 8, 12 and 33, which in the SPR screening showed to selectively bind TolCWT
compared to the mutant control TolCDADA. Each compound binds the immobilized protein in a
concentration-dependent manner, as shown in sensorgrams in Fig. 3.3A, with a range of fast
on/off-rates. The kinetic analysis of the compounds was performed using the 1:1 Langmuir
fitting model and the results are summarized in Table 3.2, with relative kon and koff rates together
with the kinetic dissociation constant (KD). Compound 8 and 12 have a calculated KD in the
sub-micromolar range, respectively 0.3 and 0.18 µM, with a fast kon at ~106 M/s and a koff in
the range of ~10-1 molecules per second. Compound 33 shows a similar koff value, but a slightly
slower kon (~106 M/s), which leads to a KD of 3.14 µM. From the equilibrium analysis, which
plots are presented in Fig. 3.3B, the Kd confirmed the kinetic analysis (KD) for compound 8
and 12, but not for compound 33, which resulted in a better affinity with a Kd of 0.81 µM.
The biophysical binding analysis through SPR was also supported by functional analysis based
on single-channel electrophysiology, in order to evaluate possible modulation of the basal ion
current through TolCWT channel.
After single-channel measurements, compound 33 was found to interfere with the ion current
through TolCWT. In silico predictions show that compound 33 may interact with Asp371 in the
acidic pocket, as shown from the ligand interactions after docking studies (Fig. 3.4A-B).
In single-channel electrophysiology measurements, addition of compound 33 on the
extracellular side of a TolC molecule inserted in an artificial bilayer (in 1 M KCl, pH 7),
influences the ion current passing through TolC. In particular, at elevated voltages the presence
of compound 33 over increasing concentrations induces a reduction of the ion current (Fig.
3.4C, ± 175 mV). Further analyzing the recorded traces at lower voltages (-100 mV), after a
filtering step at 100 Hz, it is possible to observe a reduced current when 1 and 10 µM of the
compound is added on the extracellular side of the channel (Fig. 3.4D).
Chapter 3
57
Figure 3.3 Dose-response analysis of compounds hits selected from SPR screening. Upper panels: sensorgrams
of compound A) 8, B) 12 and C) 33 injected over TolCWT at different concentrations for 180 s and 180 s of
dissociation time. Lower panels: equilibrium (or steady-state) analysis for compounds 8, 12 and 33. All values are
representative of mean ± SEM (TolCWT n=4, TolCDADA n=2).
Chapter 3
58
Figure 3.4 Biophysical analysis of compound 33: A) 2D structure and interactions with residues in the target
pocket; B) steady-state equilibrium of SPR normalized signal to the MW; C) I/V plot of single-channel
measurement of TolCWT and comp. 33 added on the extracellular side of the channel; D) representative trace of a
single-channel recording with TolCWT and comp. 33 (1 and 10 µM) added on the extracellular side of the channel,
voltage applied -100 mV. Values showed in plot C are representative of mean ± SEM (n = 3).
Chapter 3
59
In contrast to compounds 8, 12 and 33, compound 5 has a quite distinct behavior (in Fig. 3.5A-
B). Although a close structure similarity to compound 33, compound 5 has a strong binding (>
100 % relative RU) for TolCWT. This strong binding in SPR might suggest a second site of
interaction or a different stoichiometry.
In the case of compound 5, it was observed that the effect on TolCWT conductance was
concentration-dependent, producing an increasing signal, which did not lead to a plateau (Fig.
3.5B). Compound 5 showed also a contrasting effect in electrophysiology measurements
compared to compound 33. Indeed, compound 5 induces a concentration-dependent increasing
conductance through TolCWT, at medium-to-high voltages applied (± 100 mV and ± 175 mV,
Fig. 3.5C). This is also shown in recordings at -100 mV (Fig. 3.5D). This effect could be related
to an interaction with specific residues in the periplasmic α-helices of TolC, affecting and/or
inducing opening of the channel, which resolves in an increased ion current. Control studies in
the absence of inserted TolC showed no concentration dependence of conductance on
compound 5 (data not reported). This effect of the compound it is not related to any interaction
with the bilayer, but only with membrane protein inserted in the artificial bilayer.
3.3.3 Antimicrobial activity assays. The compounds were tested for their potential
antimicrobial properties against E. coli K12, which express a functional AcrAB-TolC efflux
pump, and in E. coli ΔTolC, not expressing TolC and therefore with a limited ability for
removing toxic molecules from the intracellular environment. All 33 compounds, at 100 µM,
do not show antimicrobial activity in E. coli K12 (bacterial growth > 90 % at 24 h incubation).
While comp. 5 and its homologues (25-33) inhibit the growth of E. coli ΔTolC, reaching in the
case of comp. 27, 28 and 31 the inhibition level of the positive control CCCP, which reduces
the bacterial growth to < 5 % (100 µM, Fig. A3.1B). Hexaamminecobalt, as reported
previously20 (Chapter 2), does not inhibit bacterial growth in any of the conditions tested.
No synergistic effect of these compounds was seen in presence of sub-MIC concentrations of
erythromycin, fusidic acid or novobiocin (Table A3.3).
Chapter 3
60
Figure 3.5 Biophysical analysis of compound 5: A) 2D structure and interactions with residues in the target
pocket; B) steady-state equilibrium of SPR normalized signal to the MW; C) conductance plot of single-channel
measurement of TolCWT and FSP005 added on the extracellular side of the channel; D) representative trace of a
single-channel recording with TolCWT and comp. 5 (1 and 10 µM) added on the extracellular side of the channel,
voltage applied -100 mV. Values showed in plots B and C are representative of mean ± SEM of at least 3 replicates
(*p<0.05, **p<0.005).
Chapter 3
61
Compound kon [(1/(M·s)] koff [1/s] KD [µM] Kd [µM] IC50 [µM]
8 1.59 x 106 4.87 x 10
-1 0.31 0.30 ± 0.07 >10
12 3.17 x 105 7.00 x 10
-2 0.14 0.14 ± 0.04 n/a
33 1.77 x 105 5.66 x 10
-1 3.12 0.81 ± 0.19 >10
HC 4.09 x 105 6.40 x 10
-1 1.56 0.74 ± 0.50 >100
Table 3.2 Kinetic and equilibrium analysis of the compounds binding affinity for TolCWT: kon, association rate;
koff, dissociation rate; KD, dissociation constant derived from kinetic analysis (Koff/Kon); Kd, dissociation constant
derived from equilibrium (or steady-state) analysis. IC50, Inhibition constant of the compounds on bacterial
growth. All values are representative of the mean ± SD of at least 3 replicates for each compound.
Chapter 3
62
Chapter 3
63
3.4 Discussion
For this part of my project, I combined an in silico high-throughput screening to an in vitro
investigation for the identification of small molecules binding the outer membrane protein E.
coli TolC. From the virtual screening 33 compounds were identified, that for a combination of
their chemical properties, orientation and interaction with the target residues were considered
as most promising. Through different validation steps the group was restricted to 3 compounds,
which are able to selectively bind the periplasmic tip of the TolC protein. These compounds
are shown to specifically interact with the aspartate rings, as revealed by the docking analysis
and confirmed with SPR experiments. This biophysical approach allowed us to quantify the
binding affinity of the compounds 8, 12 and 33 for TolCWT and to investigate the low affinity
for TolCDADA. Kinetic on- and off-rates were determined together with the KD, which was then
compared to the Kd values from the steady-state analysis.
Compound 33 showed a Kd of 0.81 µM and selectivity for TolCWT against TolCDADA
in an SPR
assay, suggesting an interaction of this molecule with the aspartate residues in the acidic pocket
at the periplasmic end of TolC, which has been then supported by its effect in modulating the
basal ion current of TolCWT in single-channel measurements.
This compound also did not show antimicrobial activity on E. coli strains, although it did not
either have synergistic effect in presence of sub-MIC concentrations of antibiotics like
erythromycin and fusidic acid, known substrates of the efflux pump AcrAB-TolC.
Interesting results were observed with regard to compound 5, which shows selectivity for
TolCWT in binding assays, but with ambiguous affinity and the strong tendency to increase the
conductance of TolC. A better characterization of the binding mode of this molecule might
bring more insights into the opening mode of action of TolC, the residues involved in this
process and their molecular interactions.
The results presented in this chapter led for the first time to the identification of compounds (8,
12 and 33), which are able to specifically interact with E. coli TolC in biophysical cell-free
binding assays with sub-micromolar Kd and also to interfere (in the case of compound 33) with
the ion current in single-channel measurements. Further validation with computational and
structural studies would be necessary to better understand at a molecular level the interactions
between this compound and TolC residues involved.
Chapter 3
64
To conclude, these findings are relevant to create the basis for the development of more potent
and selective compounds able to bind and block TolC not only in vitro, but also in cell-based
assays, with the ultimate goal of blocking the efflux of antibiotics and function as adjuvants in
antimicrobial therapies.
Chapter 3
65
References
1. Amaral, L., Martins, A., Spengler, G. & Molnar, J. Efflux pumps of Gram-negative bacteria: What they
do, how they do it, with what and how to deal with them. Front. Pharmacol. 4 JAN, 1–11 (2013).
2. Li, X. Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-
negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
3. Nikaido, H. & Zgurskaya, H. I. AcrAB and related multidrug efflux pumps of Escherichia coli. J. Mol.
Microbiol. Biotechnol. 3, 215–8 (2001).
4. Nikaido, H. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178, 5853–5859 (1996).
5. Opperman, T. J. & Nguyen, S. T. Recent advances toward a molecular mechanism of efflux pump
inhibition. Front. Microbiol. 6, 421 (2015).
6. Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug resistance efflux
pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob. Agents
Chemother. 45, 105–116 (2001).
7. Lamers, R. P., Cavallari, J. F. & Burrows, L. L. The efflux inhibitor phenylalanine-arginine beta-
naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One 8,
e60666 (2013).
8. Sjuts, H. et al. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful
pyranopyridine derivatives. Proc. Natl. Acad. Sci. U. S. A. 113, 3509–14 (2016).
9. Abdali, N. et al. Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane
Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump. ACS Infect. Dis. 3, 89–98 (2017).
10. Chen, Z. et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in
multidrug resistance: A review of the past decade. (2015). doi:10.1016/j.canlet.2015.10.010
11. Bikadi, Z. et al. Predicting P-glycoprotein-mediated drug transport based on support vector machine and
three-dimensional crystal structure of P-glycoprotein. PLoS One 6, (2011).
12. Zgurskaya, H. I., Krishnamoorthy, G., Ntreh, A. & Lu, S. Mechanism and function of the outer
membrane channel TolC in multidrug resistance and physiology of enterobacteria. Front. Microbiol. 2,
1–13 (2011).
13. Benz, R., Maier, E. & Gentschev, I. TolC of Escherichia coli functions as an outer membrane channel.
Zentralbl. Bakteriol. 278, 187–96 (1993).
14. Koronakis, V., Sharff, a, Koronakis, E., Luisi, B. & Hughes, C. Crystal structure of the bacterial
membrane protein TolC central to multidrug efflux and protein export. Nature 405, 914–919 (2000).
15. Du, D. et al. Structure of the AcrAB-TolC multidrug efflux pump. Nature 509, 512–5 (2014).
Chapter 3
66
16. Daury, L. et al. Tripartite assembly of RND multidrug efflux pumps. Nat. Commun. 7, 10731 (2016).
17. Jeong, H. et al. Pseudoatomic Structure of the Tripartite Multidrug Efflux Pump AcrAB-TolC Reveals
the Intermeshing Cogwheel-like Interaction between AcrA and TolC. Structure 24, 272–276 (2016).
18. Andersen, C., Koronakis, E., Hughes, C. & Koronakis, V. An aspartate ring at the TolC tunnel entrance
determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44, 1131–
1139 (2002).
19. Higgins, M. K. et al. Structure of the ligand-blocked periplasmic entrance of the bacterial multidrug
efflux protein TolC. J. Mol. Biol. 342, 697–702 (2004).
20. Gilardi, A. et al. Biophysical characterization of E. coli TolC interaction with the known blocker
hexaamminecobalt. Biochim. Biophys. Acta - Gen. Subj. 1861, 2702–2709 (2017).
21. Irwin, J. J. & Shoichet, B. K. ZINC--a free database of commercially available compounds for virtual
screening. J. Chem. Inf. Model. 45, 177–82 (2005).
22. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings. Adv.
Drug Deliv. Rev. 23, 3–25 (1997).
23. Reynolds, C. H., Tounge, B. A. & Bembenek, S. D. Ligand Binding Efficiency: Trends, Physical Basis,
and Implications. J. Med. Chem. 51, 2432–2438 (2008).
24. Jabeen, I., Pleban, K., Rinner, U., Chiba, P. & Ecker, G. F. Structure−Activity Relationships, Ligand
Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug
Transporter P-Glycoprotein. doi:10.1021/jm201705f
25. Rogers, D. J. & Tanimoto, T. T. A Computer Program for Classifying Plants. Science (80-. ). 132,
(1960).
26. Bavro, V. N. et al. Assembly and Channel Opening in a Bacterial Drug Efflux Machine. Mol. Cell 30,
114–121 (2008).
27. Pos, K. M. & Diederichs, K. Purification, crystallization and preliminary diffraction studies of AcrB, an
inner-membrane multi-drug efflux protein. Acta Crystallogr. Sect. D Biol. Crystallogr. 58, 1865–1867
(2002).
28. Mueller, P., Rudin, D. O., Ti Tien, H. & Wescott, W. C. Reconstitution of Cell Membrane Structure in
vitro and its Transformation into an Excitable System. Nature 194, 979–980 (1962).
29. Okazaki, M. et al. VDAC3 gating is activated by suppression of disulfide-bond formation between the
N-terminal region and the bottom of the pore. Biochim. Biophys. Acta - Biomembr. 1848, 3188–3196
(2015).
30. Benz, R., Janko, K., Boos, W. & Läuger, P. Formation of large, ion-permeable membrane channels by
the matrix protein (porin) of Escherichia coli. Biochim. Biophys. Acta - Biomembr. 511, 305–319
Chapter 3
67
(1978).
31. Balouiri, M., Sadiki, M. & Ibnsouda, S. K. Methods for in vitro evaluating antimicrobial activity: A
review. J. Pharm. Anal. (2016). doi:10.1016/j.jpha.2015.11.005
32. Levy, S. B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36,
695–703 (1992).
Chapter 3
68
Chapter 3
69
Annex Chapter 3 (A3)
Table A3.1 Benchmarking for the selection of virtual screening protocol.
PDB ID Resolution (Å) Best rancked RMSD (Å) Distance (Å)1LL9 1.89 24 2.74 3.4
1O86 2 21 1.50 3.09
1Y20 1.4 15 0.08 0.19
2BR5 2.83 8 0.27 0.77
2DQM 1.6 3 2.21 0.18
2J8R 1.55 2 1.42 5.16
2PFE 1.44 11 0.66 15.4
3M50 2.6 26 2.05 5.8
4MQF 2.22 26 0.3 0.58
PDB ID Resolution (Å) Best rancked RMSD (Å) Distance (Å)1LL9 1.89 28 2.26 4.17
1O86 2 15 1.86 2.9
1Y20 1.4 16 1.53 0.26
2BR5 2.83 16 0.29 0.75
2DQM 1.6 3 1.61 0.37
2J8R 1.55 2 0.90 0.72
2PFE 1.44 23 0.36 7.64
3M50 2.6 2 2.08 2.8
4MQF 2.22 1 0.38 0.28
PDB ID Resolution (Å) Best rancked RMSD (Å) Distance (Å)1LL9 1.89 29 1.73 3.73
1O86 2 11 0.82 2.04
1Y20 1.4 14 0.03 0.14
2BR5 2.83 15 1.29 3.64
2DQM 1.6 27 0.49 0.29
2J8R 1.55 29 0.84 2.92
2PFE 1.44 19 0.47 15.56
3M50 2.6 13 2.08 2.57
4MQF 2.22 5 0.09 0.28
PDB ID Resolution (Å) Best rancked RMSD (Å) Distance (Å)1LL9 1.89 4 2.70 3.29
1O86 2 19 1.28 1.48
1Y20 1.4 17 0.04 0.09
2BR5 2.83 20 0.51 1.28
2DQM 1.6 1 0.74 0.29
2J8R 1.55 18 1.20 0.63
2PFE 1.44 23 0.76 7.18
3M50 2.6 26 1.82 5.21
4MQF 2.22 6 0.13 0.28
ChemScore
GoldScore
ASP
ChemPLP
Chapter 3
70
Compound n. Structure
1
2
3
4
5
6
7
8
9
Chapter 3
71
10
11
12
13
14
15
16
17
18
Chapter 3
72
19
20
21
22
23
24
25
26
27
Chapter 3
73
28
29
30
31
32
33
Table A3.2 Compounds name and corresponding 2D structures
Chapter 3
74
Figure A3.1 Antimicrobial activity screening: A) compounds tested at 100 and 33.3 µM (0.1% DMSO v/v) in E.
coli K12; B) compounds tested at 100 and 33.3 µM (0.1% DMSO v/v) in E. coli ΔTolC.
Chapter 3
75
Figure A3.2 A) Dose-response of erythromycin and fusidic acid and synergistic effect of compound 5 in presence
of sub-MIC concentrations (for E. coli ΔTolC) of each antibiotic in E. coli K12 at 24h incubation. B) Dose-
response of erythromycin and fusidic acid and synergistic effect of FSP005 in presence of sub-MIC concentrations
(for E. coli ΔTolC) of each antibiotic in E. coli ΔTolC at 24h incubation. C) Summary table with IC50 values and
goodness of fit (R square). Errors in SD, n=2.
Table A3.3 Synergy-test: compounds tested in presence of sub-MIC concentrations of antibiotics in E. coli
ΔTolC.
IC50 FSP025 FSP026 FSP027 FSP028 FSP029 FSP030 FSP031 FSP032 FSP033 CCCP
Only compound > 100 > 100 31.55 41.28 n/a > 100 45.57 > 100 > 100 1.511
+ Erythromycin ~ 94,08 0.2187 ~ 11,22 ~ 27,63 n/a n/a ~ 29,49 n/a n/a 2.463
+ Fusidic acid > 100 112.3 24.76 45.41 235.6 > 100 50.94 n/a > 100 1.439
+ Novobiocin > 100 ~ 99,07 28.64 34.41 > 100 0.09 49.53 > 100 n/a 1.573
Chapter 3
76
77
Chapter 4
Conclusion
Within this project the important role of TolC as a target for the development of a new class of
EPIs was re-established. The majority of the efflux inhibitors identified to date target the inner
membrane protein E. coli AcrB (or its analogues) or the membrane fusion protein AcrA. TolC,
as the main outer membrane channel of efflux pumps in gram-negative bacteria, represents the
last step of the translocation process of antibiotics. Targeting TolC has the consequence of
blocking the last opportunity for bacteria to eliminate many classes of antimicrobial molecules
from the cell interior. For antibacterial compounds subject to high levels of AcrAB-TolC efflux,
such as erythromycin, fusidic acid or novobiocin, extending their time of action and improving
their efficacy may provide an opportunity to extend their useful application as medicines in a
world with a shrinking number of efficacious antibiotics.
During this 3-year project, a broad multi-disciplinary approach has been taken, which exploits
a range of methods commonly used in industrial drug discovery and development. These
methods have led to the identification of small molecules which could act as the basis for the
future development of TolC blockers. The process followed a funneling approach to
incrementally prioritize and select for fewer and fewer compounds of successively superior
properties, eliminating those with unclear or undesirable mechanisms of action or properties.
This process of identifying compounds started from in silico studies with a large virtual
screening campaign, continuing with the validation and biophysical characterization through in
vitro tests.
As a starting point for the investigations, a detailed biophysical analysis of a known blocker of
the TolC channel, hexaamminecobalt, was performed in order to establish the basis for the
successive characterization of alternative and improved potential blockers. From this qualitative
and quantitative analysis we could identify the binding constant between hexaamminecobalt
and TolCWT from single-channel measurement and steady-state analysis in SPR measurements,
respectively ks = 1.42 ± 0.4 (Fig. A2.3) and Kd = 0.74 ± 0.5 µM (Fig. 2.6).
The compounds selected from the virtual screening and docking studies for the binding to the
acidic pocket in the periplasmic tip of TolC, were further filtered through SPR screening for
their selective binding to TolCWT as compared to the mutated recombinant protein TolCDADA
Chapter 4
78
(where the aspartate residues were mutated to alanines, fig. 3.2). From this selection, three
compounds were then tested for the definition of their binding constant to TolCWT in SPR
measurements, as shown in fig. 3.3. It was possible to identify one compound (n. 33) which
appears to binds selectively TolCWT with a binding constant of 0.81 µM (Fig. 3.4 and table 3.2)
and it is furthermore able to reduce the ion current through the reconstituted channel in an
artificial bilayer setup (Figure 3.4C-D). The compound was tested for its antimicrobial activity
against E. coli, showing toxicity and proving to be a good potential EPI. Although, in
synergistic tests in presence of sub-MIC concentrations of antibiotics which are known
substrates of the AcrAB-TolC efflux pump (erythromycin, fusidic acid and novobiocin)
compound 33 did not lead to synergistically improved antibiotic performance. This suggests
that the compound may have a reduced binding affinity in vivo or potentially when TolC, in
complex and active, is in its open conformation.
Even though these findings represent a novelty in the field of efflux pump inhibitors, further
characterization of the binding mode of the identified hit compound would be necessary.
Indeed, structural studies of TolC in complex with the compound would reveal which protein
residues are involved in the binding and which chemical moieties of the compound are
important for this interaction. Based on this approach, the future outcomes a lead optimization
process might be the natural follow-up for the development of better leads with improved
activity both in vitro e in vivo as well as more drug-like features, taking in consideration factors
like toxicity and metabolism in mammalian cells and tissues.
From a technical perspective, the approach established for this PhD project includes a series of
novel methodologies applied to a challenging target such as a membrane channel. For the in
silico studies, a large virtual screening campaign was performed for the first time against a
bacterial membrane channel, such as TolC, and for which half million compounds was docked
against the target pocket. Using a combination of the two most powerful software in the market,
GOLD and MOE, we could achieve the goal of creating a large compound database to be
employed for docking in a semi-automated way. Furthermore, the protocol established could
be employed for more extensive docking campaigns with different virtual compounds libraries.
Regarding the biophysical characterization of the selected hits, single-channel current
measurements on reconstituted TolC proteins and SPR were chosen to define the binding
interactions between target and putative blockers. Both allow the recording of interaction events
in real-time and label free conditions.
Chapter 4
79
While electrophysiology is a challenging, but well-established method for the study of
membrane channels, for this class of targets SPR technology has just began to be adapted to the
needs of membrane-bound proteins (according to PubMed and Google Scholar searching tools
< 100 scientific articles have been published on this topic in the last 20 years). The reason for
this lack of extensive knowledge lays in the more challenging assay developments mainly due
to the stability and solubility of membrane proteins and the associated difficulties in keep them
into their native or near-native states.
Nevertheless, we were able to establish a working protocol for the screening of small molecules
against immobilized TolC which could be further developed for high-throughput screening, to
test larger in-house compound libraries or commercial libraries for repurposing objectives.
Furthermore, the same protocol could be applied to TolC homologues or similar bacterial
channels.
To conclude, the work presented in this thesis represents not only advances in drug discovery,
re-establishing TolC as drug target candidate for the development of EPIs, making these
compounds available to a wider community in order to be used for further elucidation of the
potential of TolC, but also an up to date methodological approach for the identification and
characterization of putative blockers and/or modulators of membrane associated transporter
channels.
Chapter 4
80
81
List of figures and tables:
Figure 1.1 Model of antibiotics discovery and development
Figure 1.2 Antibiotic resistance: acquisition pathways, main mechanisms and antibiotic targets
Figure 1.3 Diagrammatic comparison of the five families of efflux pumps
Figure 1.4 Schematic cartoon of the transport mechanism
Figure 2.1 X-ray crystal structure of TolC with bound hexaamminecobalt (PDB ID: 1TTQ).
Figure 2.2 Single-channel conductance measurements in 1 M KCl pH 7.0
Figure 2.3 I/V plot of single-channel measurements for TolCWT in absence and presence of hexaamminecobalt.
Figure 2.4 Representative current (I) vs time traces of single-channel measurements with a) TolCWT alone and in b) presence of hexaamminecobalt at 10 µM and applied voltage of -175 mV in 1 M KCl pH
Figure 2.5 Single-channel conductance measurements of TolCWT
Figure 2.6 a) Sensorgram of hexaamminecobalt injected at various concentrations over immobilized TolCWT and b) TolCDADA; c) equilibrium binding analysis of hexaamminecobalt injected over immobilized TolCWT and TolCDADA.
Figure 2.7 Antimicrobial activity of hexaamminecobalt and CCCP tested in E. coli K12 and
E. coli ΔTolC cultures; evaluation of synergistic effects of either hexaamminecobalt or CCCP
in presence of 6.5 µM erythromycin in E. coli K12 and E. coli ΔTolC; evaluation of synergistic
effects of either hexaamminecobalt or CCCP in presence of 6 µM fusidic acid in E. coli K12
and E. coli ΔTolC.
Figure A2.1 Schematic representation of TolC orientation when inserted in an artificial bilayer (left side addition).
Figure A2.2 I/V plot of single-channel measurements of TolCWT. Voltage applied ±10-60 mV, in 1 M KCl pH 7.
Figure A2.3 Hexaamminecobalt titration in single-channel conductance measurements of TolCWT, voltage applied -175 mV, buffer 1 M KCl, pH 7.
Figure A2.4 DMSO tolerance of E. coli K12 and K12-ΔTolC cultures at different incubation time-points.
Figure A2.5. Antimicrobial activity of hexaamminecobalt and CCCP titrations in E. coli K12 and E. coli ΔTolC cultures (6h incubation).
Figure 3.1 Virtual screening workflow.
82
Figure 3.2 SPR screening.
Figure 3.3 Dose-response analysis of compounds hits selected from SPR screening.
Figure 3.4 Biophysical analysis of compound 33.
Figure 3.5 Biophysical analysis of compound 5.
Table 3.2 Kinetic and equilibrium analysis of the compounds binding affinity for TolCWT
Table A3.1 Benchmarking for the selection of virtual screening protocol.
Table A3.2 Compounds name and corresponding 2D structures
Figure A3.1 Antimicrobial activity screening.
Figure A3.2 A) Dose-response of erythromycin and fusidic acid and synergistic effect of
compound 5 in presence of sub-MIC concentrations (for E. coli ΔTolC) of each antibiotic in E.
coli K12 at 24h incubation. B) Dose-response of erythromycin and fusidic acid and synergistic
effect of FSP005 in presence of sub-MIC concentrations (for E. coli ΔTolC) of each antibiotic
in E. coli ΔTolC at 24h incubation. C) Summary table with IC50 values and goodness of fit (R
square).
Table A3.3 Synergy-test: compounds tested in presence of sub-MIC concentrations of
antibiotics in E. coli ΔTolC.
83
List of publications:
- Biophysical characterization of E. coli TolC interaction with the known blocker
hexaamminecobalt
A. Gilardi, S.P. Bhamidimarri, M. Brönstrup, U. Bilitewski, R. K. R. Marreddy, K.M. Pos, B. Lorraine, P. Gribbon, M. Winterhalter, B. Windshügel
Published in the scientific journal Biochimica et Biophysica Acta - General Subjects, Volume 1861, Issue 11, Part A, November 2017, Pages 2702-2709.
DOI: 10.1016/j.bbagen.2017.07.014
- Structure-Based Discovery of Small Organic Molecules Binding to and Blocking
TolC
A. Gilardi, U. Bilitewski, M. Brönstrup, K.M. Pos, A. Razeto, E. Sassetti, M. Winterhalter, P. Gribbon, B. Windshügel
Submitted to the scientific journal Scientific Reports, (in revision).
84
Top Related